<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic therapy for pelvic inflammatory disease - Savaris, RF - 2020 | Cochrane Library</title> <meta content="Antibiotic therapy for pelvic inflammatory disease - Savaris, RF - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010285.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic therapy for pelvic inflammatory disease - Savaris, RF - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010285.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010285.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic therapy for pelvic inflammatory disease" name="citation_title"/> <meta content="Ricardo F Savaris" name="citation_author"/> <meta content="UFRGS-FAMED" name="citation_author_institution"/> <meta content="rsavaris@hcpa.edu.br" name="citation_author_email"/> <meta content="Daniele G Fuhrich" name="citation_author"/> <meta content="UFRGS-FAMED" name="citation_author_institution"/> <meta content="Jackson Maissiat" name="citation_author"/> <meta content="Universidade Federal do Rio Grande do Sul" name="citation_author_institution"/> <meta content="Rui V Duarte" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Jonathan Ross" name="citation_author"/> <meta content="The Whittall Street Clinic" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010285.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010285.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010285.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010285.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminoglycosides [adverse effects, therapeutic use]; Anti-Bacterial Agents [adverse effects, *therapeutic use]; Azithromycin [adverse effects, therapeutic use]; Cephalosporins [adverse effects, therapeutic use]; Clindamycin [adverse effects, therapeutic use]; Doxycycline [adverse effects, therapeutic use]; Drug Therapy, Combination; Nitroimidazoles [adverse effects, therapeutic use]; Pelvic Inflammatory Disease [*drug therapy, microbiology]; Publication Bias; Quinolones [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010285.pub3&amp;doi=10.1002/14651858.CD010285.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010285\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010285\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010285.pub3",title:"Antibiotic therapy for pelvic inflammatory disease",firstPublishedDate:"Aug 20, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane STI Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010285.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010285.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010285.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010285.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010285.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010285.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010285.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010285.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010285.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010285.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13739 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010285.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/appendices#CD010285-sec-0141"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/table_n/CD010285StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/table_n/CD010285StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic therapy for pelvic inflammatory disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#CD010285-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ricardo F Savaris</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#CD010285-cr-0005">Daniele G Fuhrich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#CD010285-cr-0006">Jackson Maissiat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#CD010285-cr-0007">Rui V Duarte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information#CD010285-cr-0008">Jonathan Ross</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information/en#CD010285-sec-0151">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010285.pub3">https://doi.org/10.1002/14651858.CD010285.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010285-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010285-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010285-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010285-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010285-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010285-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD010285-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010285-abs-0001" lang="en"> <section id="CD010285-sec-0001"> <h3 class="title" id="CD010285-sec-0001">Background</h3> <p>Pelvic inflammatory disease (PID) affects 4% to 12% of women of reproductive age. The main intervention for acute PID is broad‐spectrum antibiotics administered intravenously, intramuscularly or orally. We assessed the optimal treatment regimen for PID.  </p> </section> <section id="CD010285-sec-0002"> <h3 class="title" id="CD010285-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of antibiotic regimens to treat PID.</p> </section> <section id="CD010285-sec-0003"> <h3 class="title" id="CD010285-sec-0003">Search methods</h3> <p>In January 2020, we searched the Cochrane Sexually Transmitted Infections Review Group's Specialized Register, which included randomized controlled trials (RCTs) from 1944 to 2020, located through hand and electronic searching; CENTRAL; MEDLINE; Embase; four other databases; and abstracts in selected publications. </p> </section> <section id="CD010285-sec-0004"> <h3 class="title" id="CD010285-sec-0004">Selection criteria</h3> <p>We included RCTs comparing antibiotics with placebo or other antibiotics for the treatment of PID in women of reproductive age, either as inpatient or outpatient treatment. We limited our review to a comparison of drugs in current use that are recommended by the 2015 US Centers for Disease Control and Prevention guidelines for treatment of PID. </p> </section> <section id="CD010285-sec-0005"> <h3 class="title" id="CD010285-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Two authors independently extracted data, assessed risk of bias and conducted GRADE assessments of the quality of evidence. </p> </section> <section id="CD010285-sec-0006"> <h3 class="title" id="CD010285-sec-0006">Main results</h3> <p>We included 39 RCTs (6894 women) in this review, adding two new RCTs at this update. The quality of the evidence ranged from very low to high, the main limitations being serious risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency, and serious imprecision. </p> <p>None of the studies reported quinolones and cephalosporins, or the outcomes laparoscopic evidence of resolution of PID based on physician opinion or fertility outcomes. Length of stay results were insufficiently reported for analysis. </p> <p><b>Regimens containing azithromycin versus regimens containing doxycycline</b> </p> <p>We are uncertain whether there was a clinically relevant difference between azithromycin and doxycycline in rates of cure for mild‐moderate PID (RR 1.18, 95% CI 0.89 to 1.55; 2 RCTs, 243 women; I<sup>2</sup> = 72%; very low‐quality evidence). The analyses may result in little or no difference between azithromycin and doxycycline in rates of severe PID (RR 1.00, 95% CI 0.96 to 1.05; 1 RCT, 309 women; low‐quality evidence), or adverse effects leading to discontinuation of treatment (RR 0.71, 95% CI 0.38 to 1.34; 3 RCTs, 552 women; I<sup>2</sup> = 0%; low‐quality evidence). In a sensitivity analysis limited to a single study at low risk of bias, azithromycin probably improves the rates of cure in mild‐moderate PID (RR 1.35, 95% CI 1.10 to 1.67; 133 women; moderate‐quality evidence), compared to doxycycline.  </p> <p><b>Regimens containing quinolone versus regimens containing cephalosporin</b> </p> <p>The analysis shows there may be little or no clinically relevant difference between quinolones and cephalosporins in rates of cure for mild‐moderate PID (RR 1.05, 95% CI 0.98 to 1.14; 4 RCTs, 772 women; I<sup>2</sup> = 15%; low‐quality evidence), or severe PID (RR 1.06, 95% CI 0.91 to 1.23; 2 RCTs, 313 women; I<sup>2</sup> = 7%; low‐quality evidence). We are uncertain whether there was a difference between quinolones and cephalosporins in adverse effects leading to discontinuation of treatment (RR 2.24, 95% CI 0.52 to 9.72; 6 RCTs, 1085 women; I<sup>2</sup> =  0%; very low‐quality evidence). </p> <p><b>Regimens with nitroimidazole versus regimens without nitroimidazole</b> </p> <p>There was probably little or no difference between regimens with or without nitroimidazoles (metronidazole) in rates of cure for mild‐moderate PID (RR 1.02, 95% CI 0.95 to 1.09; 6 RCTs, 2660 women; I<sup>2</sup> = 50%; moderate‐quality evidence), or severe PID (RR 0.96, 95% CI 0.92 to 1.01; 11 RCTs, 1383 women; I<sup>2</sup> = 0%; moderate‐quality evidence). The evidence suggests that there was little to no difference in in adverse effects leading to discontinuation of treatment (RR 1.05, 95% CI 0.69 to 1.61; 17 studies, 4021 women; I<sup>2</sup> = 0%; low‐quality evidence). . In a sensitivity analysis limited to studies at low risk of bias, there was little or no difference for rates of cure in mild‐moderate PID (RR 1.05, 95% CI 1.00 to 1.12; 3 RCTs, 1434 women; I<sup>2</sup> = 0%; high‐quality evidence). </p> <p><b>Regimens containing clindamycin plus aminoglycoside versus quinolone</b> </p> <p>We are uncertain whether quinolone have little to no effect in  rates of cure for mild‐moderate PID compared to clindamycin plus aminoglycoside (RR 0.88, 95% CI 0.69 to 1.13; 1 RCT, 25 women; very low‐quality evidence). The analysis may result in little or no difference between quinolone vs. clindamycin plus aminoglycoside in severe PID (RR 1.02, 95% CI 0.87 to 1.19; 2 studies, 151 women; I<sup>2</sup> =  0%; low‐quality evidence). We are uncertain whether quinolone reduces adverse effects leading to discontinuation of treatment (RR 0.21, 95% CI 0.02 to 1.72; 3 RCTs, 163 women; I<sup>2</sup> =  0%; very low‐quality evidence). </p> <p><b>Regimens containing clindamycin plus aminoglycoside versus regimens containing cephalosporin</b> </p> <p>We are uncertain whether clindamycin plus aminoglycoside improves the rates of cure for mild‐moderate PID compared to cephalosporin (RR 1.02, 95% CI 0.95 to 1.09; 2 RCTs, 150 women; I<sup>2</sup> =  0%; low‐quality evidence). There was probably little or no difference in rates of cure in severe PID with clindamycin plus aminoglycoside compared to cephalosporin (RR 1.00, 95% CI 0.95 to 1.06; 10 RCTs, 959 women; I<sup>2</sup>= 21%; moderate‐quality evidence). We are uncertain whether clindamycin plus aminoglycoside reduces adverse effects leading to discontinuation of treatment compared to cephalosporin (RR 0.78, 95% CI 0.18 to 3.42; 10 RCTs, 1172 women; I<sup>2</sup> =  0%; very low‐quality evidence). </p> </section> <section id="CD010285-sec-0007"> <h3 class="title" id="CD010285-sec-0007">Authors' conclusions</h3> <p>We are uncertain whether one treatment was safer or more effective than any other for the cure of mild‐moderate or severe PID </p> <p>Based on a single study at a low risk of bias, a macrolide (azithromycin) probably improves the rates of cure of mild‐moderate PID, compared to tetracycline (doxycycline). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010285-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010285-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010285-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010285-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010285-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010285-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010285-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010285-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010285-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD010285-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010285-abs-0002" lang="en"> <h3>Treatment for pelvic inflammatory disease</h3> <p><b>Review question</b> </p> <p>We assessed the effectiveness and safety of different treatments for pelvic inflammatory disease (PID) that are recommended by current clinical guidelines for treatment of PID (the 2015 US Centers for Disease Control and Prevention guidelines for treatment of PID). </p> <p><b>Background</b> </p> <p>PID is an infection of the upper part of the woman's reproductive system (the womb, the tubes that connect the womb and ovaries, where the egg travels along), the ovaries (which make eggs), and inside the pelvis). It is a common condition affecting women of childbearing age. Symptoms of PID range from none to severe. If effective treatment is not started promptly, the consequences can be infertility (unable to have children), pregnancies outside the womb, and chronic pelvic pain (pain in the lower tummy). There is a wide range of treatment options. The choice is based on severity of symptoms, experience of the doctor, national/international guidelines, and rate of side effects. We wanted to learn if there is a preferable antibiotic (used to treat bacterial infections) therapy with high rates of cure and few side effects to treat PID. </p> <p><b>Studies characteristics</b> </p> <p>We searched the available literature up to 10 January 2020 and included 39 studies with 6894 women with an average of 14 days of treatment and follow‐up (monitoring after treatment). These trials included women of childbearing age with mild to severe PID. Trials mostly used a single or a combination of antibiotics with different administration routes: intravenous (into a blood vessel), intramuscular (into the muscle), and oral (as a tablet). In mild‐moderate cases, intramuscular and oral treatments were prescribed, and in moderate‐severe cases, treatments were usually started in hospital and were completed at home. </p> <p><b>Key results</b> </p> <p>We are uncertain whether one treatment was safer or more effective than any other for the cure of PID. From a single study, at low risk of bias, the use of a macrolide probably improves the rates of cure in mild‐moderate PID.  </p> <p>Apart from one high quality result in one comparison, the quality of the evidence ranged from very low to moderate, the main problems being serious risk of bias (poor reporting of study methods; doctors and women may have known which medicine was given), and results differed across studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010285-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010285-sec-0136"></div> <h3 class="title" id="CD010285-sec-0137">Implications for practice</h3> <section id="CD010285-sec-0137"> <p>We found no conclusive evidence that one regimen is safer or more effective than any other for the cure of PID, and there is no clear evidence for the use of nitroimidazoles (metronidazole) compared to other drugs with activity over anaerobes. Moderate‐quality evidence from a single study at low risk of bias suggests that a macrolide (azithromycin) may be more effective than a tetracycline (doxycycline) for curing mild‐moderate PID. There was probably little or no difference in rates of cure between metronidazole or no metronidazole in mild‐moderate or severe PID.  Our review considers only the drugs that are in current use and mentioned by the US Centers for Disease Control and Prevention (CDC). </p> </section> <h3 class="title" id="CD010285-sec-0138">Implications for research</h3> <section id="CD010285-sec-0138"> <p>There is a need for high‐quality randomized controlled trials to assess treatments for women with PID, particularly further trials comparing PO azithromycin versus PO doxycycline and with or without nitroimidazoles. Of note, the comparison against nitroimidazoles must be with drugs without activity against anaerobic bacteria. The lack of a consistent outcome to assess response to therapy is a major limitation. For instance, some authors have used a reduction of 70% of initial pain over a period of time to assess this outcome. This approach may seem adequate; however, consider two cases, both on a 10‐point visual analog scale: one woman started with a pain score of 10 out of 10 and the other with a pain score of 5 out of 10. After treatment, both cases report a pain score of 2. The former would be considered as cured and the latter not. Therefore, there is a clear need for core outcome measures to be developed that take into account the different effect measures in use. </p> <p>Long term sequelae, such as infertility, chronic pelvic pain, and the incidence of ectopic pregnancy should be collected and analyzed prospectively in randomized clinical trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010285-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010285-sec-0008"></div> <div class="table" id="CD010285-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Regimens containing macrolides (azithromycin) compared to regimens containing tetracycline (doxycycline) for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Azithromycin compared to doxycycline for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing azithromycin </p> <p><b>Comparison:</b> regimens containing doxycycline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with doxycycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>689 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818 per 1000</p> <p>(740 to 876)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> </p> <p>(0.89 to 1.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 13</p> <p>NNTH 3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clinical cure</b> according to criteria established by study author </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> <p>Sensitivity analysis restricted to study at low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>627 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848 per 1000</p> <p>(743 to 921)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> </p> <p>(1.10 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 5 (3 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 13–18 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>969 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 per 1000<br/>(940 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.96 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 16</p> <p>NNTH 29</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: range 13–18 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(30 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> </p> <p>(0.38 to 1.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 13</p> <p>NNTH 101</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>980 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(900 to 1000)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.98 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 10</p> <p>NNTH 8</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(741 to 1000)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.76 to 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(1 RCT)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Just 1 RCT found cases of <i>N gonorrhoeae</i><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious inconsistency (I<sup>2</sup> = 72%).<br/><sup>c</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups.<br/><sup>d</sup>Downgraded one level for serious imprecision: single study with only 98 events.<br/><sup>e</sup>Downgraded two levels for very serious risk of bias: single unblinded study with poor reporting of methods. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010285-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regimens containing quinolone compared to regimens containing cephalosporins for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Quinolone compared to cephalosporins for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> quinolone </p> <p><b>Comparison:</b> cephalosporins </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cephalosporins</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with quinolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>719 per 1000<br/>(677 to 760) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.98 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>772<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 9</p> <p>NNTH 64</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/>(622 to 766) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.91 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 7</p> <p>NNTH 15</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(5 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.24</b> </p> <p>(0.52 to 9.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1085<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6 RCTs (502 women) did not contribute to this analysis because the authors reported 0 events. </p> <p>NNTB 40</p> <p>NNTH 129</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>952 per 1000<br/>(773 to 992) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.84 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 4</p> <p>NNTH 11</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>952 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000<br/>(744 to 965) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.89 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 23</p> <p>NNTH 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups.<br/><sup>c</sup>Downgraded two levels for very serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only seven events overall. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010285-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Regimens containing nitroimidazole compared to no nitroimidazole for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Nitroimidazole compared to regimens without use of nitroimidazole for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing nitroimidazole </p> <p><b>Comparison:</b> regimens containing no nitroimidazole </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no nitroimidazole</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with nitroimidazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>766 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781 per 1000<br/>(727 to 834) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.95 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2660<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 19</p> <p>NNTH 91</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> <p>Sensitivity analysis restricted to studies at low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> <p>(740 to 868)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(1.00 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 19</p> <p>NNTH 91</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>832 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>804 per 1000<br/>(772 to 831) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> </p> <p>(0.92 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 15</p> <p>NNTH 76</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(13 to 32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.69 to 1.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4021<br/>(17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/17 studies (1088 women) did not contribute data to the analysis because the authors reported no events. </p> <p>NNTB 108</p> <p>NNTH 121</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not applicable, nitroimidazoles have no activity against chlamydia.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not applicable, nitroimidazoles have no activity against gonorrhoea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results were insufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported any fertility outcomes.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of selection, performance, detection, attrition, and reporting bias in one or more studies).<br/><sup>b</sup>Substantial inconsistency (I<sup>2</sup> = 50%). Not downgraded because of all inconsistency related to a single small study (30 women) which barely influenced the overall estimate.<br/><sup>c</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only 79 events overall. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010285-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing quinolone for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Clindamycin + aminoglycoside compared to quinolone for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing clindamycin + aminoglycoside </p> <p><b>Comparison:</b> regimens containing quinolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with quinolone</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clindamycin + aminoglycoside</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>867 per 1000</p> <p>(621 to 962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.69 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 3</p> <p>NNTH 6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/>(714 to 887) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.87 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 7</p> <p>NNTH 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> </p> <p>(0.02 to 1.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 RCTs (25 women) did not contribute data to the analysis because the authors reported 0 events. </p> <p>NNTB 8</p> <p>NNTH 273</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(722 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.85 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (3 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 3</p> <p>NNTH 5</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(920 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR  1.00</b> (0.96 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (3 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias: single unblinded study with poor reporting of methods.<br/><sup>b</sup>Downgraded two levels for serious imprecision (though further downgrading not possible): confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, very few events overall.<br/><sup>c</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in both studies).<br/><sup>d</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010285-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing cephalosporin for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Clindamycin + aminoglycoside compared to cephalosporin for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing clindamycin + aminoglycoside </p> <p><b>Comparison:</b> regimens containing cephalosporin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cephalosporin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clindamycin + aminoglycoside</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>958 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>974 per 1000</p> <p>(911 to 993)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.95 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11</p> <p>NNTH 19</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>840 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838 per 1000<br/>(801 to 870) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.95 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>959<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 21</p> <p>NNTH 22</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(2 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.18 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1172<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/10 RCTs (617 women) did not contribute data to the analysis reported because the authors reported no events. </p> <p>NNTB 75</p> <p>NNTH 126</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> 946 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962 per 1000<br/>(893 to 987)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.94 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(5 RCTs)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 9</p> <p>NNTH 16</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>983 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(962 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.99 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 17</p> <p>NNTH 43</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95 CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious imprecision, small overall sample size.<br/><sup>c</sup>Downgraded two levels for serious imprecision (though further downgrading not possible): confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only six events overall. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010285-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010285-sec-0009"></div> <section id="CD010285-sec-0010"> <h3 class="title" id="CD010285-sec-0010">Description of the condition</h3> <p>Pelvic inflammatory disease (PID) in women describes inflammation of the upper genital tract and surrounding structures as a result of ascending infection from the lower genital tract – bacteria spread directly from the cervix to the endometrium and on to the upper genital tract (<a href="./references#CD010285-bbs2-0183" title="SoperDE . Pelvic inflammatory disease. Obstetrics and Gynecology2010;116(2 Pt 1):419-28.">Soper 2010</a>). The signs and symptoms of PID are not specific and may range from asymptomatic to serious illness. PID can produce endometritis, parametritis (infection of the structures near the uterus), salpingitis (infection of the fallopian tubes), oophoritis (infection of the ovary), and tubo‐ovarian abscess (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). Peritonitis (infection inside the peritoneum, the thin layer of tissue lining the abdomen) and perihepatitis (infection around the liver) can also occur. Peritonitis, tubo‐ovarian abscess, and severe systemic illness (e.g. fever and malaise) are considered severe forms of PID; the other forms of presentation are considered mild or moderate according to the subjective opinion of the examining doctor or nurse (<a href="./references#CD010285-bbs2-0183" title="SoperDE . Pelvic inflammatory disease. Obstetrics and Gynecology2010;116(2 Pt 1):419-28.">Soper 2010</a>). </p> <p>The most common complaint of PID is lower abdominal pain, with or without vaginal discharge. Specific grading of the clinical presentation using symptom scores has been described (e.g. <a href="./references#CD010285-bbs2-0169" title="McCormackWM , NowrooziK , AlpertS , SackelSG , LeeYH , LoweEW , et al. Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride. Sexually Transmitted Diseases1977;4(4):125-31.">McCormack 1977</a>; <a href="./references#CD010285-bbs2-0077" title="HagerWD , PascuzziM , VernonM . Efficacy of oral antibiotics following parenteral antibiotics for serious infections in obstetrics and gynecology. Obstetrics &amp; Gynecology1989;73(3 Pt 1):326-29. ">Hager 1989</a>), but has not been validated, and use of these scores is inconsistent. PID does not have a diagnostic gold standard. The most commonly used diagnostic criteria are based on those from the Centers for Disease Control and Prevention (CDC) (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>), namely sexually active young women and other women at risk for sexually transmitted disease (STD) who are experiencing recent pelvic or lower abdominal pain where no cause other than PID can be identified, and one or more of the following minimum criteria are present on pelvic examination: cervical motion tenderness, uterine tenderness, or adnexal tenderness. The requirement for all three minimum criteria to be present increases the specificity of the diagnosis but reduces sensitivity. </p> <p>Two sexually transmitted infections (<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>) have been strongly implicated in the aetiology of PID (<a href="./references#CD010285-bbs2-0173" title="NewmanL , RowleyJ , Vander HoornS , WijesooriyaNS , UnemoM , LowN , et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PloS One2015;10(12):e0143304. [DOI: 10.1371/journal.pone.0143304]">Newman 2015</a>); however, based on the pattern of organisms isolated from the upper genital tract, the infection may often be polymicrobial (caused by more than one type of bacteria) (<a href="./references#CD010285-bbs2-0159" title="EschenbachDA , BuchananTM , PollockHM , ForsythPS , AlexanderER , LinJS , et al. Polymicrobial etiology of acute pelvic inflammatory disease. New England Journal of Medicine1975;293(4):166-71.">Eschenbach 1975</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0153" title="BavejaG , SainiS , SangwanK , AroraDR . A study of bacterial pathogens in acute pelvic inflammatory disease. Journal of Communicable Diseases2001;88:121-5.">Baveja 2001</a>; <a href="./references#CD010285-bbs2-0164" title="HaggertyCL , NessRB . Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Review of Anti-infective Therapy2006;4(2):235-47.">Haggerty 2006</a>). This suggests that initial damage produced by <i>C trachomatis</i> or <i>N gonorrhoeae</i> may permit the opportunistic entry of other bacteria, including anaerobes (bacteria that do not need oxygen to grow) (<a href="./references#CD010285-bbs2-0178" title="RossJD . Pelvic inflammatory disease. American Family Physician2014;90(10):725-6.">Ross 2014a</a>). However, in many cases, no infection is found in the lower genital tract (<a href="./references#CD010285-bbs2-0161" title="GollerJL , De LiveraAM , FairleyCK , GuyRJ , BradshawCS , ChenMY , et al. Population attributable fraction of pelvic inflammatory disease associated with chlamydia and gonorrhoea: a cross-sectional analysis of Australian sexual health clinic data. Sexually Transmitted Infections2016;92(7):525-31. [DOI: 10.1136/sextrans-2015-052195] [PMID: 27091729]">Goller 2016</a>). </p> <p>The public health importance of PID can be estimated from the frequency of chlamydial and gonococcal infections. In 2012, among women aged 15 to 49 years, the estimated global prevalence of chlamydia was 3.4% (95% confidence interval (CI) 2.5% to 4.5%), gonorrhoea was 2% (95% CI 1.4% to 2.8%), and trichomoniasis was 4.0% (95% CI 2.7% to 5.8%) (<a href="./references#CD010285-bbs2-0180" title="RowleyJ , HoornVS , KorenrompE , LowN , UnemoM , AbuRaddadLJ , et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization2019;97:548-62. [DOI: 10.2471/BLT.18.228486]">Rowley 2019</a>). In one prospective study of 1170 women with elevated risk for having chlamydial cervicitis, 8.6% developed PID within three years; among women with chlamydia, the risk ratio (RR) for developing PID was 2.5 (95% CI 1.5 to 4.0) (<a href="./references#CD010285-bbs2-0172" title="NessRB , SmithKJ , ChangCC , SchistermanEF , BassDC , Gynecologic Infection Follow-Through, GIFT, Investigators. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sexually Transmitted Diseases2006;33(3):137-42.">Ness 2006</a>). In the UK, the prevalence of PID is about 2% among women between 16 and 46 years old (<a href="./references#CD010285-bbs2-0181" title="SimmsI , RogersP , CharlettA . The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales. International Journal of STD and AIDS1999;10(7):448-51.">Simms 1999</a>; <a href="./references#CD010285-bbs2-0156" title="DattaSD , TorroneE , Kruszon-MoranD , BermanS , JohnsonR , SatterwhiteCL , et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sexually Transmitted Diseases2012;39(2):92-6.">Datta 2012</a>; <a href="./references#CD010285-bbs2-0178" title="RossJD . Pelvic inflammatory disease. American Family Physician2014;90(10):725-6.">Ross 2014a</a>). However, in some other countries, the rates of chlamydia infection are lower, for example, in Jordan it is 0.6% in symptomatic women and 0.5% in asymptomatic women (<a href="./references#CD010285-bbs2-0168" title="MahafzahAM , Al-RamahiMQ , Asa'dAM , El-KhateebMS . Prevalence of sexually transmitted infections among sexually active Jordanian females. Sexually Transmitted Diseases2008;35(6):607-10.">Mahafzah 2008</a>). Among women with PID, 10% to 20% may become infertile, 40% will develop chronic pelvic pain, and 10% of those who conceive will have an ectopic pregnancy (<a href="./references#CD010285-bbs2-0154" title="BlanchardJF , MosesS , GreenawayC , OrrP , HammondGW , BrunhamRC . The evolving epidemiology of chlamydial and gonococcal infections in response to control programs in Winnipeg, Canada. American Journal of Public Health1998;88(10):1496-502.">Blanchard 1998</a>; <a href="./references#CD010285-bbs2-0116" title="NessRB , SoperDE , HolleyRL , PeipertJ , RandallH , SweetRL , et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. American Journal of Obstetric and Gynecology2002;186(5):929-37. [PMID: 12015517]">Ness 2002</a>; <a href="./references#CD010285-bbs2-0117" title="NessRB , TrautmannG , RichterHE , RandallH , PeipertJF , NelsonDB , et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease a randomized trial. Obstetrics and Gynaecology2005;106(3):573-80. ">Ness 2005</a>; <a href="./references#CD010285-bbs2-0168" title="MahafzahAM , Al-RamahiMQ , Asa'dAM , El-KhateebMS . Prevalence of sexually transmitted infections among sexually active Jordanian females. Sexually Transmitted Diseases2008;35(6):607-10.">Mahafzah 2008</a>). </p> <p>The morbidity associated with PID relates to the acute inflammatory process, which can cause abdominal pain, vaginal discharge, dyspareunia (pain during sexual intercourse), and abnormal menstrual bleeding. In addition, long‐term complications secondary to tubal damage occur and include chronic pelvic pain, ectopic pregnancy, and infertility (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). PID has a prevalence of between 2% and 12%, and it cannot be diagnosed reliably from clinical symptoms and signs, which have a positive predictive value for salpingitis of only 65% to 90% compared with laparoscopy (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>; <a href="./references#CD010285-bbs2-0155" title="Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2018. www.cdc.gov/std/stats18/womenandinf.htm#pid (accessed prior to 27 May 2020).">CDC 2018</a>). Direct visualization of the fallopian tubes via laparoscopy has a higher sensitivity, but there is considerable inter‐ and intra‐observer reproducibility (<a href="./references#CD010285-bbs2-0170" title="MolanderP , FinneP , SjobergJ , SellorsJ , PaavonenJ . Observer agreement with laparoscopic diagnosis of pelvic inflammatory disease using photographs. Obstetrics and Gynecology2003;101:875-80.">Molander 2003</a>). Endometrial biopsy may have some utility (<a href="./references#CD010285-bbs2-0176" title="RossJD . What is endometritis and does it require treatment?Sexually Transmitted Infections2004;80(4):252-3.">Ross 2004</a>), but is not performed routinely and is of uncertain diagnostic and prognostic value, since endometritis (infection of the inner mucosal lining of the uterus) can persist despite the resolution of clinical symptoms (<a href="./references#CD010285-bbs2-0116" title="NessRB , SoperDE , HolleyRL , PeipertJ , RandallH , SweetRL , et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. American Journal of Obstetric and Gynecology2002;186(5):929-37. [PMID: 12015517]">Ness 2002</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>). </p> <p>The financial cost of pelvic infection has been estimated to exceed USD 2.4 billion in the USA, and the mean total cost per episode is around USD 5000 (<a href="./references#CD010285-bbs2-0186" title="TrentM , EllenJM , FrickKD . Estimating the direct costs of pelvic inflammatory disease in adolescents: a within-system analysis. Sexually Transmitted Diseases2011;38(4):326-8.">Trent 2011</a>). In the UK, the mean cost of a non‐complicated episode of PID is GBP 163 (<a href="./references#CD010285-bbs2-0150" title="AghaizuA , AdamsEJ , TurnerK , KerryS , HayP , SimmsI , et al. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia trachomatis? Cost analysis of the Prevention of Pelvic Infection (POPI) trial. Sexually Transmitted Infections2011;87(4):312-7.">Aghaizu 2011</a>). </p> </section> <section id="CD010285-sec-0011"> <h3 class="title" id="CD010285-sec-0011">Description of the intervention</h3> <p>The main intervention for acute PID is the use of broad‐spectrum antibiotics which cover <i>C trachomatis</i> , <i>N gonorrhoeae</i>, and anaerobic bacteria. There are three effective routes of administration (intravenous (IV), intramuscular (IM), or oral (PO)) (<a href="./references#CD010285-bbs2-0116" title="NessRB , SoperDE , HolleyRL , PeipertJ , RandallH , SweetRL , et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. American Journal of Obstetric and Gynecology2002;186(5):929-37. [PMID: 12015517]">Ness 2002</a>; <a href="./references#CD010285-bbs2-0188" title="WalkerCK , WiesenfeldH . Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clinical Infectious Diseases2007;28 (Suppl 1):S29-36.">Walker 2007</a>). In refractory cases, surgery to drain an abscess or hydrosalpinx may be necessary. When parenteral treatment is used, it is usually discontinued 24 hours after a woman improves clinically (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). </p> <p>The optimal treatment strategy is unclear. A variety of antibiotic regimens have been used, with marked geographical variation. Current practice generally involves the use of multiple agents to cover <i>C trachomatis</i> , <i>N gonorrhoeae</i>, and anaerobic bacteria, but the best combination of agents is unknown. The background prevalence and antimicrobial resistance patterns of bacterial pathogens in different regions may influence the choice of empirical therapy. </p> <p>Guidelines have been produced in the USA (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>), and Europe (<a href="./references#CD010285-bbs2-0167" title="JudlinP . Current concepts in managing pelvic inflammatory disease. Current Opinion in Infectious Diseases2010;23(1):83.">Judlin 2010a</a>; <a href="./references#CD010285-bbs2-0179" title="RossJ , JudlinP , JensenJ . 2012 European guideline for the management of pelvic inflammatory disease. International Journal of STD &amp; AIDS2014;25(1):1-7. [PMID: 24216035]">Ross 2014b</a>), to guide therapy, but these have not been based on a formal systematic review. In addition, to choose an antibiotic for PID treatment, it is necessary to consider its spectrum, cost, adverse effects, and posology (i.e. dosage, interval) to achieve the best balance between compliance and efficacy. There are no current systematic reviews on this topic. </p> <p>The different antibiotic regimens proposed to treat PID vary in cost, efficacy, and adverse effects. Potential adverse effects include allergic reactions and gastrointestinal symptoms, which can lead to discontinuation of therapy. Lack of evidence is revealed in the current CDC and British Association for Sexual Health and HIV (BASHH) guidelines, where the authors state that there is limited evidence for the need to eradicate anaerobes and for the use of alternative regimens, such as azithromycin (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>), and the comparison between clindamycin plus aminoglycoside and fluoroquinolones (<a href="./references#CD010285-bbs2-0179" title="RossJ , JudlinP , JensenJ . 2012 European guideline for the management of pelvic inflammatory disease. International Journal of STD &amp; AIDS2014;25(1):1-7. [PMID: 24216035]">Ross 2014b</a>). Likewise, if the prevalence of <i>N gonorrhoeae</i> is low, the use of fluoroquinolones can be considered if allergy to cephalosporin is an issue (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). </p> </section> <section id="CD010285-sec-0012"> <h3 class="title" id="CD010285-sec-0012">How the intervention might work</h3> <p>It is likely that the intervention works by eradicating bacterial pathogens and reducing the associated inflammation which leads to scarring. Necrotic tissue and pus present in an abscess may prevent antibiotics reaching the infected area. Mechanical drainage of the abscess through open surgery, laparoscopy, or aspiration through a large‐bore needle is likely to work by removing infected material which antibiotics are unable to treat (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). Clinical cure without surgery in women with a tubo‐ovarian abscess is around 75% (<a href="./references#CD010285-bbs2-0157" title="DeWittJ , ReiningA , AllsworthJE , PeipertJF . Tuboovarian abscess: is size associated with duration of hospitalization and complications?Obstetrics and Gynecology International2010;2010:1-5. [DOI: 10.1155/2010/847041]">DeWitt 2010</a>). The rationale for using broad‐spectrum antibiotics is to cover the wide variety of pathogens found in PID, which include gram‐positive (e.g. <i>Streptococcus</i> ), gram‐negative (e.g. <i>Chlamydia</i> , <i>Klebsiella</i> , <i>Escherichia coli</i> , <i>Neisseria</i> ), and anaerobic bacteria (gram positive or negative: <i>Peptostreptococcus</i> , <i>Bacteroides</i>). </p> </section> <section id="CD010285-sec-0013"> <h3 class="title" id="CD010285-sec-0013">Why it is important to do this review</h3> <p>PID is a common disease; for women aged 35 to 44 years in England, it is estimated that 33.6% have experienced at least one episode of PID, diagnosed or not (<a href="./references#CD010285-bbs2-0174" title="PriceMJ , AdesAE , WeltonNJ , SimmsI , HornerPJ . Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England. Epidemiology and Infection2017;145(1):208-15. [PMID: 27678278]">Price 2017</a>). PID is accompanied by high rates of morbidity in young women (<a href="./references#CD010285-bbs2-0116" title="NessRB , SoperDE , HolleyRL , PeipertJ , RandallH , SweetRL , et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. American Journal of Obstetric and Gynecology2002;186(5):929-37. [PMID: 12015517]">Ness 2002</a>; <a href="./references#CD010285-bbs2-0171" title="MorrisGC , StewartCM , SchoemanSA , WilsonJD . A cross-sectional study showing differences in the clinical diagnosis of pelvic inflammatory disease according to the experience of clinicians: implications for training and audit. Sexually Transmitted Infections2014;90(6):445-51. [DOI: 10.1136/sextrans-2014-051646]">Morris 2014</a>). It requires effective treatment to reduce the incidence of chronic pelvic pain, infertility, and transmitted STDs. A variety of antibiotic regimens have been proposed to treat PID, which vary in cost, efficacy, and adverse effects, but the optimal treatment strategy is unclear. </p> <p>Currently there are no systematic reviews of this subject and the optimal treatment strategy is unclear. This review will address clinical questions raised by current guidelines on the treatment of PID (<a href="./references#CD010285-bbs2-0179" title="RossJ , JudlinP , JensenJ . 2012 European guideline for the management of pelvic inflammatory disease. International Journal of STD &amp; AIDS2014;25(1):1-7. [PMID: 24216035]">Ross 2014b</a>; <a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>), regarding the effectiveness and safety of nitroimidazole, the relative benefits of azithromycin versus doxycycline, the use of quinolones, and the relative benefits of cephalosporins compared to the most‐used regimen of clindamycin plus aminoglycoside, to inform future guideline development and clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010285-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010285-sec-0014"></div> <p>To assess the effectiveness and safety of antibiotic regimens to treat PID.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010285-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010285-sec-0015"></div> <section id="CD010285-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010285-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs), including those which did not describe their method of randomization (i.e. where the authors stated that treatment was randomized without providing further details). We chose randomized trials as they provide the strongest evidence for evaluating the efficacy of therapy (<a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We included studies irrespective of publication status or language. </p> <p>We excluded quasi‐randomized trials because they produce effect estimates indicating more extreme benefits when compared with RCTs (<a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We also excluded cross‐over and cluster trials. </p> </section> <section id="CD010285-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women of reproductive age (14 years or older) diagnosed as having acute PID (symptoms for less than six weeks) based on clinical findings, laparoscopy, endometrial biopsy, or detectable gonorrhoea or chlamydia in the upper genital tract. </p> <p>We divided women into two groups: mild‐moderate (e.g. absence of tubo‐ovarian abscess) and severe (e.g. systemically unwell, presence of tubo‐ovarian abscess). </p> </section> <section id="CD010285-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We limited our review to comparison of drugs in current use that are recommended for consideration by the 2015 US CDC guidelines for treatment of PID (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). </p> <p>We included trials that contained, at least, the following treatments for PID:</p> <p> <ul id="CD010285-list-0001"> <li> <p>azithromycin versus doxycycline;</p> </li> <li> <p>quinolone versus cephalosporin;</p> </li> <li> <p>nitroimidazole versus no nitroimidazole;</p> </li> <li> <p>clindamycin plus aminoglycoside versus quinolone;</p> </li> <li> <p>clindamycin plus aminoglycoside versus cephalosporin.</p> </li> </ul> </p> </section> <section id="CD010285-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The following outcomes were measured.</p> <section id="CD010285-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010285-list-0002"> <li> <p>Effectiveness: clinical cure according to the criteria defined by the treating physician (e.g. resolution or improvement of signs and symptoms related to PID). </p> </li> <li> <p>Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy. </p> </li> </ul> </p> </section> <section id="CD010285-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010285-list-0003"> <li> <p>Microbiological clearance of <i>C trachomatis</i> (chlamydia) from either the upper or lower genital tract, according to the method provided by the authors. </p> </li> <li> <p>Microbiological clearance of <i>N gonorrhoeae</i> (gonorrhoea) from either the upper or lower genital tract, according to the method provided by the authors. </p> </li> <li> <p>Laparoscopic evidence of resolution of PID based on physician opinion.</p> </li> <li> <p>Length of stay (for inpatient care).</p> </li> <li> <p>Fertility outcome based on at least one participant‐reported live birth following PID treatment in women not using effective contraception. </p> </li> </ul> </p> <p>Where studies included women with various types of pelvic infection, we considered only women with endometritis, salpingitis, parametritis, or oophoritis (not related to labour, delivery, cancer, or surgery). </p> <p>Where studies reported multiple time points, we considered the period between 14 and 28 days after initiation of treatment. </p> </section> </section> </section> <section id="CD010285-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We identified relevant RCTs of 'antibiotic therapy' for 'PID', irrespective of their language of publication, publication date, and publication status (published, unpublished, in press, and in progress). We used both electronic searching in bibliographic databases and handsearching, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <section id="CD010285-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We contacted the Information Specialist of the Cochrane Sexually Transmitted Infections Review Group to implement a comprehensive search strategy capturing as many relevant RCTs as possible in electronic databases. We used a combination of controlled vocabulary (MeSH, Emtree, DeCS, including exploded terms) and free‐text terms (considering spelling variants, synonyms, acronyms, and truncation) for 'pelvic inflammatory disease (PID)' and 'antibiotic therapy', with field labels, proximity operators, and Boolean operators. We presented the search strategies in <a href="./appendices#CD010285-sec-0142">Appendix 1</a>. Specifically, we searched the following electronic databases. </p> <p> <ul id="CD010285-list-0004"> <li> <p>The Cochrane Sexually Transmitted Infections Review Group's Specialized Register, which includes RCTs from 1944 to 2020 located through electronic searching and handsearching. The electronic databases searched for the register are the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. </p> </li> <li> <p>CENTRAL, Ovid platform (1991 to 10 January 2020).</p> </li> <li> <p>MEDLINE, Ovid platform (1946 to 10 January 2020).</p> </li> <li> <p>MEDLINE In‐Process &amp; Other Non‐Indexed Citations, Ovid platform (1946 to 10 January 2020).</p> </li> <li> <p>MEDLINE Daily Update, Ovid platform (1946 to 10 January 2020).</p> </li> <li> <p>Embase (1947 to 10 January 2020).</p> </li> <li> <p>LILACS, iAHx interface (1982 to 10 January 2020).</p> </li> <li> <p>Web of Science (2001 to 10 January 2020).</p> </li> </ul> </p> <p>In MEDLINE, we used the Cochrane Highly Sensitive Search Strategy for identifying RCTs: sensitivity and precision maximizing version (2008 revision), Ovid format (<a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). The LILACS search strategy combined RCTs filter of iAHx interface. </p> </section> <section id="CD010285-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following trials registers:</p> <p> <ul id="CD010285-list-0005"> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>). </p> </li> </ul> </p> <p>We searched for grey literature in OpenGrey (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>) (from 1993 to 2014). We contacted authors of all RCTs identified by other methods as well as pharmaceutical companies producing 'antibiotic therapy' for 'pelvic inflammatory disease (PID).' </p> <p>We handsearched conference proceeding abstracts in the following publications: <i>Indian Journal of Sexually Transmitted Diseases</i> (2008 to January 2020), <i>Sexually Transmitted Diseases</i> (1974 to January 2020), <i>Sexually Transmitted Infections</i> (1996 to January 2020), <i>Journal of Sexual Medicine</i> (2004 to January 2020), <i>Sexual and Relationship Therapy</i> (2000 to January 2020), and the Society for the Scientific Study of Sexuality's <i>Sexual Science Newsletter</i> (2000 to January 2020). </p> <p>We handsearched previous systematic reviews on similar topics identified from:</p> <p> <ul id="CD010285-list-0006"> <li> <p>the Cochrane Library (<a href="http://www.thecochranelibrary.com/" target="_blank">www.thecochranelibrary.com/</a>); </p> </li> <li> <p>Epistemonikos (<a href="http://www.epistemonikos.org/" target="_blank">www.epistemonikos.org/</a>). </p> </li> </ul> </p> <p>We handsearched the reference lists of all identified RCTs.</p> </section> </section> <section id="CD010285-sec-0026"> <h3 class="title" id="CD010285-sec-0026">Data collection and analysis</h3> <section id="CD010285-sec-0027"> <h4 class="title">Selection of studies</h4> <p>In this updated version, two review authors (DGF and JM) performed an initial screen of titles and abstracts retrieved by the updated search, and we retrieved the full text of all potentially eligible studies. Two review authors (DGF and JM) independently examined these studies for compliance with the inclusion criteria and selected studies that met these criteria. We resolved disagreements regarding eligibility by discussion or by consulting a third review author (RFS). We documented the selection process in a PRISMA flow chart. We excluded pelvic infection related to obstetric surgical procedures or in animals. Where a study contained both 'eligible' and 'ineligible' participants, we included a subset of data relating to the 'eligible' participants if sufficient details were provided for analysis. </p> </section> <section id="CD010285-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DGF, JM) independently extracted the data from each study using a data extraction form that the review authors designed and pilot tested. We collected data from the included studies in sufficient detail to complete the <a href="./references#CD010285-sec-0169" title="">Characteristics of included studies</a> table. We also extracted detailed numerical outcome data in duplicate to allow calculation of Mantel‐Haenszel RRs for each comparison. We examined data for errata, retraction, fraud, and inconsistencies. We resolved disagreements by consensus or by consulting a fourth review author (JR or RFS). </p> <p>If a study had more than two intervention arms, we included or combined only those that met the predefined inclusion criteria. For instance, if the study compared azithromycin (group A) versus azithromycin plus metronidazole (group B) versus metronidazole plus cefoxitin or doxycycline (group C), and the analysis was between the use or not of metronidazole, we combined groups B and C versus group A. The treatment effect was expressed as rate of cure (%) and its magnitude and direction checked in forest plots to ensure consistency with the original study. Where studies had multiple publications, we used the main trial report as the reference and derived additional details from secondary papers. We corresponded with study investigators for further data as required. </p> <p>Data collected with the data extraction form included:</p> <p> <ul id="CD010285-list-0007"> <li> <p>Study factors:</p> <ul id="CD010285-list-0008"> <li> <p>author, date of publication, journal;</p> </li> <li> <p>date of study;</p> </li> <li> <p>study design;</p> </li> <li> <p>location;</p> </li> <li> <p>setting;</p> </li> <li> <p>quality of randomization, treatment allocation, and blinding;</p> </li> <li> <p>method of PID diagnosis;</p> </li> <li> <p>sample size.</p> </li> </ul> </li> <li> <p>Participant factors:</p> <ul id="CD010285-list-0009"> <li> <p>age, ethnicity;</p> </li> <li> <p>pregnancy;</p> </li> <li> <p>presence of intrauterine device (IUD);</p> </li> <li> <p>duration of symptoms;</p> </li> <li> <p>presence of abscess (pyosalpinx, tubo‐ovarian abscess).</p> </li> </ul> </li> <li> <p>Outcome measured:</p> <ul id="CD010285-list-0010"> <li> <p>method of assessment of pelvic pain and score;</p> </li> <li> <p>timing of assessment;</p> </li> <li> <p>adverse events;</p> </li> <li> <p>additional assessments of outcome: laparoscopy, microbiology, fertility.</p> </li> </ul> </li> <li> <p>Intervention factors:</p> <ul id="CD010285-list-0011"> <li> <p>antibiotic given: dose, route, length of therapy;</p> </li> <li> <p>comparator regimen: dose, route, length of therapy;</p> </li> <li> <p>additional treatment given.</p> </li> </ul> </li> <li> <p>Additional data:</p> <ul id="CD010285-list-0012"> <li> <p>whether contact tracing was performed.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010285-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DGF, JM) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010285-bbs2-0166" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We resolved disagreements between two review authors by consensus or by involving a third review author (RFS). We assessed risk of bias using the Cochrane 'Risk of bias' tool provided in RevMan Web (<a href="./references#CD010285-bbs2-0175" title="The Cochrane CollaborationReview Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at: revman.cochrane.org.">RevMan Web 2019</a>). We provided justification for risk of bias (high, low, unclear) in the 'Risk of bias' table by direct reference to the relevant report. We requested missing information from the study investigators using open‐ended questions. </p> <section id="CD010285-sec-0030"> <h5 class="title">1. Random sequence generation (checking for possible selection bias)</h5> <p>For each included study, we verified the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD010285-list-0013"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (no randomization);</p> </li> <li> <p>unclear risk of bias (e.g. authors stated that women were randomized to one of the treatments, without further explanation).   </p> </li> </ul> </p> </section> <section id="CD010285-sec-0031"> <h5 class="title">2. Allocation concealment (checking for possible selection bias)</h5> <p>For each included study, we verified the method used to conceal allocation to interventions prior to assignment, and we assessed whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD010285-list-0014"> <li> <p>low risk of bias (e.g. telephone or central randomization; consecutively numbered, sealed, opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth); or </p> </li> <li> <p>unclear risk of bias (allocation was mentioned without further details).   </p> </li> </ul> </p> </section> <section id="CD010285-sec-0032"> <h5 class="title">3.1. Blinding of participants and personnel (checking for possible performance bias)</h5> <p>For each included study, we verified the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered studies to be at: </p> <p> <ul id="CD010285-list-0015"> <li> <p>low risk of bias if participants and personnel were blinded, or if we judged that the lack of blinding would be unlikely to affect results (e.g. culture for <i>N gonorrhoeae</i>); </p> </li> <li> <p>high risk if participants and personnel were not blinded;</p> </li> <li> <p>unclear risk of bias if no further details were provided.</p> </li> </ul> </p> </section> <section id="CD010285-sec-0033"> <h5 class="title">3.2. Blinding of outcome assessment (checking for possible detection bias)</h5> <p>For each included study, we verified the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received.  We assessed blinding separately for different outcomes or classes of outcomes. We assessed methods used to blind outcome assessment as: </p> <p> <ul id="CD010285-list-0016"> <li> <p>low risk of bias if assessors were blinded, or if we judged that the lack of blinding would be unlikely to affect results (e.g. culture for <i>N gonorrhoeae</i>); </p> </li> <li> <p>high risk if assessors were not blinded;</p> </li> <li> <p>unclear risk of bias if no further details were provided.</p> </li> </ul> </p> </section> <section id="CD010285-sec-0034"> <h5 class="title">4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data) </h5> <p>For each included study, and for each outcome or class of outcomes, we verified the completeness of data, including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re‐included missing data in the analyses we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD010285-list-0017"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomization); or </p> </li> <li> <p>unclear risk of bias: no further details were provided.</p> </li> </ul> </p> <p>We used a cutoff point of 20% missing data in determining if a study was at low or high risk of bias (<a href="./references#CD010285-bbs2-0160" title="FewtrellMS , KennedyK , SinghalA , MartinRM , NessA , Hadders-AlgraM , et al. How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?Archives of Disease in Childhood2008;93(6):458-61. [DOI: 10.1136/adc.2007.127316]">Fewtrell 2008</a>). </p> </section> <section id="CD010285-sec-0035"> <h5 class="title">5. Selective reporting (checking for reporting bias)</h5> <p>For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD010285-list-0018"> <li> <p>low risk of bias (where it was clear that all the study's prespecified outcomes and all expected outcomes of interest to the review were reported); </p> </li> <li> <p>high risk of bias (where not all the study's prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study did not include results of a key outcome that would have been expected to have been reported); or </p> </li> <li> <p>unclear risk of bias: no further details were provided.</p> </li> </ul> </p> </section> <section id="CD010285-sec-0036"> <h5 class="title">6. Other bias (checking for bias due to problems not covered by 1. to 5. above)</h5> <p>For each included study, we described any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD010285-list-0019"> <li> <p>low risk of bias;</p> </li> <li> <p>high risk of bias; or</p> </li> <li> <p>unclear whether there was risk of bias.</p> </li> </ul> </p> </section> <section id="CD010285-sec-0037"> <h5 class="title">7. Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010285-bbs2-0166" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). With reference to 1. to 6. above, we assessed the likely magnitude and direction of the bias and whether we considered that it was likely to impact on the findings.  We explored the impact of the level of bias by undertaking sensitivity analyses (see <a href="#CD010285-sec-0045">Sensitivity analysis</a>). </p> </section> </section> <section id="CD010285-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we used number of events (cure) in the control and intervention groups to calculate Mantel‐Haenszel risk ratios (RR). We presented 95% confidence intervals (CI) for all outcomes. For number need to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome, we followed the recommendation given by Altman (<a href="./references#CD010285-bbs2-0151" title="AltmanDG . Confidence intervals for the number needed to treat. BMJ1998;317(7168):1309-12.">Altman 1998</a>). When we observed a treatment effect (cure), we reported the NNTB with 95% CIs. </p> <p>When possible, we performed analysis based on intention to treat (ITT). When information for an ITT analysis was not available, we used the results provided by the authors. </p> <p>We performed meta‐analysis separately for mild‐moderate PID and severe PID. We defined severe PID as the presence of tubo‐ovarian abscess, being systemically unwell, or the presence of peritonitis; mild‐moderate PID as no presence of tubo‐ovarian abscess. We further analyzed cases in these two groups across different classes of antibiotics. </p> </section> <section id="CD010285-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The primary unit of analysis was an event per woman randomized, which was used to calculate the percentage response rate (e.g. clinical cure). </p> </section> <section id="CD010285-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed the data on an ITT basis to the greatest degree possible and made attempts to obtain missing data from the original trials. Where we were unable to obtain these data, we considered cases that were lost to follow‐up as treatment failure (worst‐case scenario) in the primary analysis. For other outcomes, we analyzed the available data. We did not analyze data from other reported outcomes (e.g. pooled rates of cure of different diseases, including PID). </p> </section> <section id="CD010285-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the I<sup>2</sup> statistic as follows: low (l<sup>2</sup> value below 40%), moderate (l<sup>2</sup> value 40% to 75%), or high (l<sup>2</sup> value above 75%) (<a href="./references#CD010285-bbs2-0185" title="SuttonAJ , HigginsJ . Recent developments in meta-analysis. Statistics in Medicine2008;27(5):625-50.">Sutton 2008</a>; <a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We also assessed statistical heterogeneity in each meta‐analysis using the t<sup>2</sup> and Chi<sup>2</sup> statistics. </p> <p>We regarded heterogeneity as substantial if the I<sup>2</sup> statistic was greater than 40% and either t<sup>2</sup> was greater than zero, or there was a low P value (less than 0.10) in the Chi<sup>2</sup> test for heterogeneity. If we detected substantial heterogeneity, we explored possible explanations for it in subgroup analyses (see <a href="#CD010285-sec-0044">Subgroup analysis and investigation of heterogeneity</a>). We took statistical heterogeneity into account when interpreting the results, especially if there was any variation in the direction of effect. If so, we used a random‐effects analysis, instead of fixed‐effect analysis. </p> </section> <section id="CD010285-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. Some types of reporting bias (e.g. publication bias, multiple publication bias, language bias, etc.) reduce the likelihood that all studies eligible for a review are retrieved (<a href="./references#CD010285-bbs2-0165" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). If all eligible studies are not retrieved, the review would be biased. In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimize their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). There are five possible causes for the asymmetric funnel plot: reporting bias, poor methodological quality, true heterogeneity, artefactual, and chance (<a href="./references#CD010285-bbs2-0158" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(629):634. [PMID: 9310563]">Egger 1997</a>). Only through formal statistical analysis or using a 'contour‐enhanced' funnel plot is an explication for these asymmetrical funnel plots possible, which was not performed herein. </p> </section> <section id="CD010285-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses using Review Manager Web (<a href="./references#CD010285-bbs2-0175" title="The Cochrane CollaborationReview Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at: revman.cochrane.org.">RevMan Web 2019</a>). We used a fixed‐effect meta‐analysis for combining data where it was reasonable to assume that trials were estimating the same underlying treatment effect (i.e. where trials were examining the same intervention, and the trials' populations and methods were sufficiently similar). We conducted separate analyses for mild‐moderate and severe PID. </p> <p>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity (I<sup>2</sup> = 40% or greater), we used a random‐effects meta‐analysis to produce an overall summary if a mean treatment effect across trials was considered clinically meaningful. We treated the random‐effects summary as the mean range of possible treatment effects, and discussed the clinical implications of treatment effects differing between trials. </p> <p>If the mean treatment effect was not clinically meaningful, we did not combine trials. Where we used random‐effects analyses, we presented the results as the mean treatment effect with 95% CIs, and the estimates of the t<sup>2</sup> and I<sup>2</sup> statistics. </p> </section> <section id="CD010285-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we performed the following prespecified subgroup analyses:</p> <p> <ul id="CD010285-list-0020"> <li> <p>route of antibiotic administration (PO, IM, or IV);</p> </li> <li> <p>length of therapy (less or more than seven continuous days of receiving antibiotics);</p> </li> <li> <p>detection of chlamydia;</p> </li> <li> <p>detection of gonorrhoea;</p> </li> <li> <p>site of initiation of treatment (inpatient or outpatient).</p> </li> </ul> </p> <p>We avoided selective reporting of a particular subgroup by not performing multiple subgroup analyses. If we identified substantial heterogeneity (I<sup>2</sup> = 40% or greater), we used a random‐effects analysis as the primary statistical analysis. </p> <p>Where there was substantial heterogeneity, we explored possible reasons for this finding by stratifying results according to the characteristics of the study population (e.g. method of PID diagnosis), the intervention (e.g. class of antibiotic used, dose of antibiotic, route of administration), or methodological characteristics (e.g. length of time to outcome measurement). </p> </section> <section id="CD010285-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook the following sensitivity analysis to investigate whether our conclusions were robust to methodological decisions made by review authors: </p> <p> <ul id="CD010285-list-0021"> <li> <p>risk of bias (restricting analysis to blinded studies at low risk of selection bias).</p> </li> </ul> </p> <section id="CD010285-sec-0046"> <h5 class="title">Summary of findings and assessment of the quality of the evidence</h5> <p>We used GRADEpro software to produce 'Summary of findings' tables (<a href="./references#CD010285-bbs2-0162" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed prior to February 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2014. Available at gradepro.org.">GRADEpro GDT</a>). The GRADE approach considers the following criteria: risk of bias, inconsistency, indirectness of evidence, imprecision, and publication bias, and specifies four levels of quality: high, moderate, low, and very low, starting from high for RCTs. If there was a flaw in the RCT, we downgraded the quality of the evidence by one or two levels. </p> <p>Two review authors independently applied GRADE in the 'Summary of findings' tables. We resolved any disagreements by consensus. We downgraded for risk of bias due to crucial risk of bias for two or more criteria. The evidence was downgraded further if there was inconsistency. Inconsistency was based on statistical test for heterogeneity and how much variation there was in the findings of the studies that contributed to the outcome. We also considered imprecision, and downgraded if the CIs were compatible with benefit in one or both groups, or with no difference between the groups. In each domain, we downgraded one level for serious risk of bias and two levels for very serious risk of bias. </p> <p>'Summary of findings' tables considering clinical cure in PID according to its severity (mild‐moderate, severe) and the number of adverse events leading to discontinuation of therapy were presented for the following comparisons of PID treatment with regimens containing: </p> <p> <ul id="CD010285-list-0022"> <li> <p>macrolides (azithromycin) compared to tetracycline (doxycycline);</p> </li> <li> <p>quinolone compared to cephalosporins;</p> </li> <li> <p>nitroimidazole compared to no nitroimidazole;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to quinolone;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to cephalosporin.</p> </li> </ul> </p> </section> </section> <section id="CD010285-sec-0047"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used GRADEpro software ( <a href="./references#CD010285-bbs2-0162" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed prior to February 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2014. Available at gradepro.org.">GRADEpro GDT</a>) to produce 'Summary of findings' tables. The GRADE approach considers the following criteria: risk of bias, inconsistency, indirectness of evidence, imprecision, and publication bias, and specifies four levels of quality: high, moderate, low, and very low, starting from high for RCTs. If there was a flaw in the RCT, we downgraded the quality of the evidence by one or two levels. </p> <p>Two review authors independently applied a consistent grading for GRADE in the 'Summary of findings' tables. We resolved any disagreements by consensus. We downgraded for risk of bias due to crucial risk of bias for two or more criteria. The evidence was downgraded further if there was inconsistency. Inconsistency was based on statistical test for heterogeneity and how much variation there was in the findings of the studies that contributed to the outcome. We also considered imprecision, and downgraded if the CIs were compatible with benefit in one or both groups, or with no difference between the groups. In each domain, we downgraded one level for serious risk of bias and two levels for very serious risk of bias. </p> <p>Summary of Findings (SoF) tables considering clinical cure in PID according to its severity (mild‐moderate, severe) and the number of adverse events leading to discontinuation of therapy were presented for the following comparisons of PID treatment with regimens containing </p> <p> <ul id="CD010285-list-0023"> <li> <p>macrolides (azithromycin) compared to tetracycline (doxycycline);</p> </li> <li> <p>quinolone compared to cephalosporins;</p> </li> <li> <p>nitroimidazole compared to no nitroimidazole;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to quinolone;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to cephalosporin</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010285-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010285-sec-0048"></div> <section id="CD010285-sec-0049"> <h3 class="title">Description of studies</h3> <p>We included 39 RCTs (two new studies) with a wide range of sample sizes and the quality of evidence ranged from very low to high by some limitations with potentially serious risk of bias. </p> <section id="CD010285-sec-0050"> <h4 class="title">Results of the search</h4> <p>In the 2017 version, we retrieved 2133 references and screened 2094 records after removing duplicated references. We discarded 1955 records as clearly irrelevant and considered 139 full‐text articles. </p> <p>For this updated version, we retrieved 479 references and screened 478 records after removing duplicate references. We discarded 68 records for not dealing with humans, 269 records for not being RCTs, 125 for not being related to PID, and six for not comparing antibiotics. We considered 10 full‐text articles. After full‐text analysis, two new studies met our inclusion criteria and they were included (<a href="#CD010285-fig-0001">Figure 1</a>). The reasons for exclusion of the eight full‐text studies are explained in the <a href="./references#CD010285-sec-0170" title="">Characteristics of excluded studies</a> table. We extracted data from the full‐text article for each study. </p> <div class="figure" id="CD010285-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. PID: pelvic inflammatory disease; RCT: randomised controlled trial." data-id="CD010285-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. PID: pelvic inflammatory disease; RCT: randomised controlled trial.</p> </div> </div> </div> </section> <section id="CD010285-sec-0051"> <h4 class="title">Included studies</h4> <p>The 39 included trials had 6894 women, with a sample size ranging from 25 (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>) to 1156 (<a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>). Retrieved studies came from a wide range of inpatient and outpatient settings from different continents (Americas, Europe, Asia, Oceania, and Africa) and were written in English, German, French, Japanese, and Italian. </p> <p>For this update, two studies, one from the UK (<a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>), and the other from the USA (<a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>), were added. <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a> compared the rate of cure between ofloxacin 400 mg twice daily plus metronidazole 400 mg twice daily for 14 days versus five days of azithromycin plus metronidazole for 14 days plus ceftriaxone IM. <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a> compared ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO twice daily for 14 days plus placebo PO twice daily for 14 days versus ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO twice daily for 14 days plus metronidazole 500 mg PO twice daily for 14 days. </p> <section id="CD010285-sec-0052"> <h5 class="title">Population</h5> <p>The included trials recruited girls and women aged 14 years and over with a diagnosis of PID according to CDC criteria (pelvic or lower abdominal pain and one or more of the following clinical criteria: cervical motion tenderness, uterine tenderness, or adnexal tenderness) (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). Studies varied in degree of disease severity of participants, treatment location (i.e. inpatient or outpatient), and countries and continents. PID was considered severe in the presence of systemically unwell women, peritonitis, or pelvic abscess. </p> </section> <section id="CD010285-sec-0053"> <h5 class="title">Interventions</h5> <p>The 39 RCTs yielded 6894 women and made the following comparisons.</p> <p>For mild‐moderate PID:</p> <p> <ul id="CD010285-list-0024"> <li> <p>macrolides (azithromycin) compared to tetracycline (doxycycline) (<a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>); </p> </li> <li> <p>quinolone compared to cephalosporins (<a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>); </p> </li> <li> <p>nitroimidazole compared to no use of nitroimidazole (<a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0019" title="HoymeUB , AnsorgR , vonRecklinghausenG , SchindlerAE . Quinolones in the treatment of uncomplicated salpingitis: ofloxacin/metronidazole vs gentamicin/clindamycin [Chinolone in der therapie der unkoplizierten salpingitis: ofloxacin/metronidazol vs gentamicin/clindamicin]. Infektionen in der Gynäcologie und geburtshilfe1993;VII.8a:607-8. ">Hoyme 1993</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>); </p> </li> <li> <p>clindamycin plus aminoglycoside compared to quinolone (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>); </p> </li> <li> <p>clindamycin plus aminoglycoside compared to cephalosporin (<a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>). </p> </li> </ul> </p> <p>For severe PID:</p> <p> <ul id="CD010285-list-0025"> <li> <p>macrolides (azithromycin) compared to tetracycline (doxycycline) (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>); </p> </li> <li> <p>quinolone compared to cephalosporins (<a href="./references#CD010285-bbs2-0027" title="OkadaH , YamamotoT , YasudaJ , KanaoM , ShimizuT , YorozuY , et al. Comparative clinical study on ciprofloxacin and cefroxadine in the treatment of infections in obstetrics and gynecology [in Japanese]. Chemotherapy1988;36(11):821-57. ">Okada 1988</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>); </p> </li> <li> <p>nitroimidazole compared to no use of nitroimidazole (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>); </p> </li> <li> <p>clindamycin plus aminoglycoside compared to quinolone (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>); </p> </li> <li> <p>clindamycin plus aminoglycoside compared to cephalosporin (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). </p> </li> </ul> </p> </section> <section id="CD010285-sec-0054"> <h5 class="title">Outcomes</h5> <p>The main outcome was clinical cure, and 5475 women were reported as clinically cured. We defined clinical cure according to the authors' definitions, which ranged from absence of symptoms for 24 hours (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>), to a 60% or greater reduction in total pain score at day 21 combined with an absence of pelvic discomfort/tenderness, temperature less than 37.8 °C, and white blood cell count less than 10,000/mm<sup>3</sup> on day 21 (<a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>). Most trials used clinical parameters for cure, that is, reduction of fever, and reduction or absence of pain at different time points after treatment. We identified adverse effects leading to discontinuation of treatment as those related to the suspension of therapeutic regimen. </p> </section> </section> <section id="CD010285-sec-0055"> <h4 class="title">Excluded studies</h4> <p>We excluded 106 studies. The most common reason for exclusion was that the study did not report a comparison of interest to this review (63 studies). Other common reasons for exclusion were that PID cases were not distinguished from other pelvic infectious conditions (26 studies), the studies were not randomized (15 studies), or were suspected of fraud (two studies) (see <a href="./references#CD010285-sec-0170" title="">Characteristics of excluded studies</a> table). </p> <p>In the updated 2020 version, we analyzed and excluded eight full‐text articles (<a href="#CD010285-fig-0001">Figure 1</a>). Two articles were not related to PID (<a href="./references#CD010285-bbs2-0048" title="BrittainC , ChildsM , DuleyL , HardingJ , HepburnT , MeakinG , et al. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. Trials2016;17(1):558. [DOI: 10.1186/s13063-016-1683-8] [PMID: 27881151]">Brittain 2016</a>; <a href="./references#CD010285-bbs2-0042" title="BaeryN ,  Ghasemi NejadA ,  AminM ,  MahroozadeS ,  MokaberinejadR ,  BioosS ,  et al. Effect of vaginal suppository on bacterial vaginitis based on Persian medicine (Iranian traditional medicine): a randomised double blind clinical study. Journal of Obstetrics and Gynaecology2018;38(8):1110-4. [DOI: 10.1080/01443615.2018.1445706] [PMID: 30084707]">Baery 2018</a>); one compared two nitroimidazoles (morinidazole and ornidazole) for treating PID (<a href="./references#CD010285-bbs2-0052" title="CaoC , LuoA , WuP , WengD , ZhengH , WangS . Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial. European Journal of Clinical Microbiology &amp; Infectious Diseases2017;36:1225-30. [DOI: 10.1007/s10096-017-2913-z] [PMID: 28265816]">Cao 2017</a>); one used a Tibetan drug with non‐inflammatory activity (Honghua Ruyi Wan) with moxifloxacin compared to moxifloxacin plus placebo (<a href="./references#CD010285-bbs2-0148" title="ZhangD , LiuZ , LinH , LiaoQ , LiS , SuiL , et al. Effectiveness of Honghua Ruyi Wan combined with antibiotics for relief of pelvic inflammatory disease pain in women. Biomedical Research2017;28(10):4665-70. ">Zhang 2017</a>); one compared two quinolones (levofloxacin and ciprofloxacin) (<a href="./references#CD010285-bbs2-0149" title="ZouH , ZhangW , WangM , LiZ . Effects of levofloxacin hydrochloride and ciprofloxacin on pelvic inflammation and risk factors related to their effects. International Journal of Clinical and Experimental Medicine2019;12(9):11754-61. ">Zou 2019</a>), which it is not a comparison we wanted; and three used traditional Chinese medicine (Kangfu, an anti‐inflammatory drug (<a href="./references#CD010285-bbs2-0115" title="NCT04035785. A clinical study on Kangfu anti-inflammatory suppository of gynaecology combined with antibiotics for pelvic inflammatory diseases (evidence of dampness and heat accumulation): a randomized, double blind, parallel Control of positive drugs, multi-center clinical study. clinicaltrials.gov/ct2/show/study/NCT04035785. ">NCT04035785</a>), gynaecological Qianjin with levofloxacin and metronidazole versus  levofloxacin and metronidazole (<a href="./references#CD010285-bbs2-0114" title="NCT04031664. A clinical study on Qianjin capsule of gynaecology combined with antibiotics for pelvic inflammatory diseases (damp-heat stasis and Qi deficiency syndrome). clinicaltrials.gov/ct2/show/NCT040316642019. ">NCT04031664</a>), and Fuyanshu capsules (<a href="./references#CD010285-bbs2-0062" title="FengXL , JiangS , ChenJ , LiuX , ZhangY , ChenL . Effect of Fuyanshu capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease. Zhongguo Zhong Yao za Zhi [China Journal of Chinese Materia Medica]2019;44(12):2637-43. ">Feng 2019</a>)). We extracted data from the full‐text article for each study (see <a href="./references#CD010285-sec-0170" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD010285-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>We performed a full risk of bias assessment on all included studies. We classified those studies where authors stated that women were randomized to one of two treatments, without further details, as at unclear risk of selection bias. Twenty‐seven studies occurred before 1996, and predated the introduction of CONSORT guidelines, so many studies had unclear risk of bias. </p> <p>We summarized the risk of bias in <a href="#CD010285-fig-0002">Figure 2</a> and <a href="#CD010285-fig-0003">Figure 3</a>. Additional details of the included trials are provided in the <a href="./references#CD010285-sec-0169" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD010285-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010285-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010285-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010285-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010285-sec-0057"> <h4 class="title">Allocation</h4> <p>Fourteen trials adequately reported a truly random process of sequence generation, for example, random number table or computer random number generator, making selection bias at entry unlikely (<a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). The remaining included trials did not report the random sequence generation methods, making the risk of selection bias at entry unclear. </p> <p>For allocation concealment, four trials implemented sequentially numbered drug containers as a concealment allocation method, making selection bias at entry unlikely (<a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>). The remaining included trials did not report the method used to conceal allocation to interventions prior to assignment, making the risk of selection bias at entry unclear. </p> </section> <section id="CD010285-sec-0058"> <h4 class="title">Blinding</h4> <p>Seven trials used placebo with an identical appearance for the control group to blind trial participants and personnel, making performance and detection bias unlikely (<a href="#CD010285-fig-0002">Figure 2</a>) (<a href="./references#CD010285-bbs2-0027" title="OkadaH , YamamotoT , YasudaJ , KanaoM , ShimizuT , YorozuY , et al. Comparative clinical study on ciprofloxacin and cefroxadine in the treatment of infections in obstetrics and gynecology [in Japanese]. Chemotherapy1988;36(11):821-57. ">Okada 1988</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). Twelve studies did not blind investigators and participants to the allocation, making them at high risk of bias (<a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>; <a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>). The remaining included trials did not specify how the participants and the personnel were blinded from knowledge of which intervention a participant received, making the risk of performance and detection bias unclear. </p> </section> <section id="CD010285-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>Completeness of data was adequate (i.e. less than 20% of data missing) for 32 of the studies (<a href="#CD010285-fig-0002">Figure 2</a>) (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0027" title="OkadaH , YamamotoT , YasudaJ , KanaoM , ShimizuT , YorozuY , et al. Comparative clinical study on ciprofloxacin and cefroxadine in the treatment of infections in obstetrics and gynecology [in Japanese]. Chemotherapy1988;36(11):821-57. ">Okada 1988</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>; <a href="./references#CD010285-bbs2-0019" title="HoymeUB , AnsorgR , vonRecklinghausenG , SchindlerAE . Quinolones in the treatment of uncomplicated salpingitis: ofloxacin/metronidazole vs gentamicin/clindamycin [Chinolone in der therapie der unkoplizierten salpingitis: ofloxacin/metronidazol vs gentamicin/clindamicin]. Infektionen in der Gynäcologie und geburtshilfe1993;VII.8a:607-8. ">Hoyme 1993</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>; <a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). </p> <p>Four studies were unclear about the risk of attrition bias (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>) </p> <p>The remaining studies had more than 20% of data missing, with an associated high risk of attrition bias. </p> </section> <section id="CD010285-sec-0060"> <h4 class="title">Selective reporting</h4> <p>The trial protocol was available for five studies, and it was clear that the published reports included all the expected outcomes, including those that were prespecified, making reporting bias unlikely (<a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). For the remaining studies, trial protocol was unavailable, and it was unclear whether the published reports included all the expected outcomes, including those that were prespecified. The reports had insufficient information to permit judgment of 'yes' or 'no' and were, therefore, at unclear risk of bias. </p> </section> <section id="CD010285-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>One study had imbalances in baseline characteristics and was at high risk of potential bias (<a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>). Out of 39 trials, 13 had some form of funding by pharmaceutical companies (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>; <a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>); however, there is no clear evidence that trial methods are more likely to be flawed if a trial is industry‐funded (<a href="./references#CD010285-bbs2-0184" title="SterneJ . Why the Cochrane risk of bias tool should not include funding source as a standard item [editorial]. Cochrane Database of Systematic Reviews2013;12:ED000076. [10.1002/14651858.ED000076]">Sterne 2013</a>), therefore these trials were at unclear risk. The remaining trials provided insufficient information to permit a judgement of 'yes' or 'no' and were, therefore, at unclear risk of bias. </p> </section> </section> <section id="CD010285-sec-0062"> <h3 class="title" id="CD010285-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD010285-tbl-0001"><b>Summary of findings 1</b> Regimens containing macrolides (azithromycin) compared to regimens containing tetracycline (doxycycline) for pelvic inflammatory disease</a>; <a href="./full#CD010285-tbl-0002"><b>Summary of findings 2</b> Regimens containing quinolone compared to regimens containing cephalosporins for pelvic inflammatory disease</a>; <a href="./full#CD010285-tbl-0003"><b>Summary of findings 3</b> Regimens containing nitroimidazole compared to no nitroimidazole for pelvic inflammatory disease</a>; <a href="./full#CD010285-tbl-0004"><b>Summary of findings 4</b> Regimens containing clindamycin plus aminoglycoside compared to regimens containing quinolone for pelvic inflammatory disease</a>; <a href="./full#CD010285-tbl-0005"><b>Summary of findings 5</b> Regimens containing clindamycin plus aminoglycoside compared to regimens containing cephalosporin for pelvic inflammatory disease</a> </p> <p>We analyzed the effectiveness of clinical cure and adverse effects leading to discontinuation of treatment in five scenarios based on drug class: </p> <p> <ul id="CD010285-list-0026"> <li> <p>macrolides (azithromycin) compared to tetracycline (doxycycline);</p> </li> <li> <p>quinolone compared to cephalosporins;</p> </li> <li> <p>nitroimidazole compared to no nitroimidazole;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to quinolone;</p> </li> <li> <p>clindamycin plus aminoglycoside compared to cephalosporin.</p> </li> </ul> </p> <p>We analyzed the efficacy of therapy in these five comparisons in women with mild‐moderate PID and women with severe PID. We also compared adverse events leading to discontinuation of the therapy. Lack of further analysis is discussed in the <a href="#CD010285-sec-0155">Differences between protocol and review</a> section. </p> <section id="CD010285-sec-0063"> <h4 class="title">1. Regimens containing macrolides (azithromycin) compared to regimens containing tetracycline (doxycycline) </h4> <p>Three studies compared azithromycin versus doxycycline in mild‐moderate (<a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>) or severe (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>) PID. </p> <section id="CD010285-sec-0064"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD010285-sec-0065"> <h5 class="title">1.1. Effectiveness</h5> <section id="CD010285-sec-0066"> <h6 class="title">1.1a. Clinical cure in mild‐moderate pelvic inflammatory disease</h6> <p>We included two trials in the analysis of clinical cure in mild‐moderate PID (<a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>). We are uncertain whether there was a clinically relevant difference between azithromycin and doxycycline in rates of cure for mild‐moderate PID (RR 1.18, 95% CI 0.89 to 1.55; 2 studies, 243 women; I<sup>2</sup> = 72%; very low‐quality evidence) (<a href="./references#CD010285-fig-0017" title="">Analysis 1.1</a>; <a href="#CD010285-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010285-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> </div> <p>This suggests that if the rate of clinical cure in women with mild‐moderate PID using regimens including doxycycline was 69%, the rate using regimens including azithromycin would be 74% to 88%. </p> <p>In a sensitivity analysis limited to the study at low risk of bias, azithromycin probably improves the rates of cure in mild‐moderate PID (RR 1.35, 95% CI 1.10 to 1.67; 1 study, 133 women; moderate‐quality evidence) (<a href="./references#CD010285-fig-0018" title="">Analysis 1.2</a>; <a href="#CD010285-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD010285-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID. </p> </div> </div> </div> <p>The evidence derived from this sensitivity analysis suggests that in mild‐moderate PID, if the rate of clinical cure in women using regimens including doxycycline was 63%, the rate using regimens including azithromycin would be 74% to 92%. </p> </section> <section id="CD010285-sec-0067"> <h6 class="title">1.1b. Clinical cure in severe pelvic inflammatory disease</h6> <p>One trial reported clinical cure in severe PID (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>). The analysis may result in little or no difference between azithromycin and doxycycline in rates of severe PID  (RR 1.00, 95% CI 0.96 to 1.05; 1 study, 309 women; low‐quality evidence) (<a href="./references#CD010285-fig-0019" title="">Analysis 1.3</a>; <a href="#CD010285-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD010285-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.3 Effectiveness of cure in severe PID." data-id="CD010285-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.3 Effectiveness of cure in severe PID. </p> </div> </div> </div> <p>This suggests that if clinical cure in severe PID in women using regimens including doxycycline was 97%, the rate using regimens including azithromycin would be 94% to 99%.  </p> </section> </section> <section id="CD010285-sec-0068"> <h5 class="title">1.2. Adverse events</h5> <section id="CD010285-sec-0069"> <h6 class="title">1.2.1. Antibiotic‐related adverse effects leading to discontinuation of therapy</h6> <p>We included three trials in the analysis of antibiotic‐related adverse effects leading to discontinuation of therapy (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>; <a href="./references#CD010285-bbs2-0023" title="MalhotraM , SharmaJB , BatraS , AroraR , SharmaS . Ciprofloxacin-tinidazole combination, fluconazole-azithromycin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian Journal of Medical Sciences2003;57(12):549-55. ">Malhotra 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>). We are uncertain of a clinically relevant difference between azithromycin and doxycycline in rates of discontinuation between the groups (RR 0.71, 95% CI 0.38 to 1.34; 3 studies, 552 women; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD010285-fig-0020" title="">Analysis 1.4</a>). </p> <p>This suggests that if the rate of adverse events in women using regimens including doxycycline was 8%, the rate using regimens including azithromycin would be 3% to 8%. </p> <p>Data are depicted in <a href="./full#CD010285-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> <section id="CD010285-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD010285-sec-0071"> <h6 class="title">1.3. Microbiological clearance of chlamydia</h6> <p>Two studies reported chlamydia clearance (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>). Cure was obtained in 49/50 women in the azithromycin group (98%, 95% CI 89% to 100%) and 33/33 women in the doxycycline group (100%, 95% CI 90% to 100%).  </p> <p>This suggests that if the rate of microbiological clearance of <i>C trachomatis</i> in women using regimens including doxycycline was 98%, the rate using regimens including azithromycin would be 90% to 100%. </p> </section> <section id="CD010285-sec-0072"> <h6 class="title">1.4. Microbiological clearance of gonorrhoea</h6> <p>Two studies reported gonorrhoea clearance (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>), but only one found evidence of <i>N gonorrhoeae</i> (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>). In the azithromycin group, there was cure in 11/11 cases (100%, 95% CI 74% to 100%). Cure was also 100% in the doxycycline group (5/5 cases; 100%, 95% CI 57% to 100%).  </p> <p>This suggests that if the rate of microbiological clearance of <i>N gonorrhoeae </i>in women using regimens including doxycycline was 100%, the rate using regimens including azithromycin would be 74% to 100%. </p> </section> <section id="CD010285-sec-0073"> <h6 class="title">1.5. Laparoscopic evidence of resolution of pelvic inflammatory disease based on physician opinion </h6> <p>We found no data for laparoscopic evidence of resolution of PID.</p> </section> <section id="CD010285-sec-0074"> <h6 class="title">1.6. Length of stay (for inpatient care)</h6> <p>One study reported length of hospital stay (<a href="./references#CD010285-bbs2-0005" title="BevanCD , RidgwayGL , RothermelCD . Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. Journal of International Medical Research2003;31(1):45-54. ">Bevan 2003</a>). Women were kept in the hospital, per protocol, for 13 to 18 days. </p> </section> <section id="CD010285-sec-0075"> <h6 class="title">1.7. Fertility outcome</h6> <p>No studies reported live birth rate.</p> </section> </section> </section> <section id="CD010285-sec-0076"> <h4 class="title">2. Regimens containing quinolones versus regimens containing cephalosporins</h4> <p>Six studies compared quinolones versus cephalosporins in mild‐moderate PID (<a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>), or severe PID (<a href="./references#CD010285-bbs2-0027" title="OkadaH , YamamotoT , YasudaJ , KanaoM , ShimizuT , YorozuY , et al. Comparative clinical study on ciprofloxacin and cefroxadine in the treatment of infections in obstetrics and gynecology [in Japanese]. Chemotherapy1988;36(11):821-57. ">Okada 1988</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>). </p> <section id="CD010285-sec-0077"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD010285-sec-0078"> <h5 class="title">2.1. Effectiveness</h5> <section id="CD010285-sec-0079"> <h6 class="title">2.1a. Clinical cure in mild‐moderate pelvic inflammatory disease</h6> <p>We included four trials in the analysis of clinical cure in mild‐moderate PID (<a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0026" title="MartensMG , GordonS , YarboroughDR , FaroS , BinderD , BerkeleyA , Ambulatory PID Research Group. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Southern Medical Journal1993;86(6):604-10. ">Martens 1993</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>; <a href="./references#CD010285-bbs2-0013" title="DeanG , WhethamJ , SoniS , KerrL , GreeneL , RossJ ,   et al. Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?Sexually Transmitted Infections2016;92 (Suppl):A3. [DOI: 10.1186/ISRCTN51790058]">Dean 2016</a>). The analysis shows there may be little or no clinically relevant difference between quinolones and cephalosporins in rates of cure  in mild‐moderate PID (RR 1.05, 95% CI 0.98 to 1.14; 4 studies, 772 women; I<sup>2</sup> = 15%; low‐quality evidence) (<a href="./references#CD010285-fig-0021" title="">Analysis 2.1</a>; <a href="#CD010285-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD010285-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> </div> <p>This suggests that if the rate of clinical cure in women with mild‐moderate PID using regimens including cephalosporins was 69%, the rate using regimens including quinolones would be 68% to 76%. </p> </section> <section id="CD010285-sec-0080"> <h6 class="title">2.1b. Clinical cure in severe pelvic inflammatory disease</h6> <p>We included two trials in the analysis of clinical cure in severe PID (<a href="./references#CD010285-bbs2-0027" title="OkadaH , YamamotoT , YasudaJ , KanaoM , ShimizuT , YorozuY , et al. Comparative clinical study on ciprofloxacin and cefroxadine in the treatment of infections in obstetrics and gynecology [in Japanese]. Chemotherapy1988;36(11):821-57. ">Okada 1988</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>). The analysis shows there may be little or no clinically relevant difference between quinolones and cephalosporins in rates of cure of severe PID (RR 1.06, 95% CI 0.91 to 1.23; 2 studies, 313 women; I<sup>2</sup> = 7%; low‐quality evidence) (<a href="./references#CD010285-fig-0022" title="">Analysis 2.2</a>; <a href="#CD010285-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD010285-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.2 Effectiveness of cure in severe PID." data-id="CD010285-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.2 Effectiveness of cure in severe PID. </p> </div> </div> </div> <p>This suggests that if clinical cure in women with severe PID using regimens including cephalosporin was 64%, the rate using regimens including quinolone would be 62% to 77%. </p> </section> </section> <section id="CD010285-sec-0081"> <h5 class="title">2.2. Adverse events</h5> <section id="CD010285-sec-0082"> <h6 class="title">2.2.1. Antibiotic‐related adverse effect leading to discontinuation of therapy</h6> <p>The trials reported few adverse effects leading to discontinuation of treatment (quinolones: 1.2%, 95% CI 0.5% to 2.9% versus cephalosporin: 0.5%, 95% CI 0.1% to 1.9%); we are uncertain whether there was a difference between quinolones and cephalosporins in rates of discontinuation (RR 2.24, 95% CI 0.52 to 9.72; 6 studies, 1085 women; I<sup>2</sup> = 0%; very low‐quality evidence) (<a href="./references#CD010285-fig-0023" title="">Analysis 2.3</a>; <a href="#CD010285-fig-0009">Figure 9</a>).  </p> <div class="figure" id="CD010285-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.3 Any antibiotic‐related adverse effect leading to discontinuation." data-id="CD010285-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.3 Any antibiotic‐related adverse effect leading to discontinuation. </p> </div> </div> </div> <p>This suggests that if the rate of adverse events in women using regimens including cephalosporin was 0.5%, the rate using regimens including quinolones would be 0.5% to 2.9%. </p> <p>Data are depicted in <a href="./full#CD010285-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> <section id="CD010285-sec-0083"> <h5 class="title">Secondary outcomes</h5> <section id="CD010285-sec-0084"> <h6 class="title">2.3. Microbiological clearance of chlamydia</h6> <p>Three studies reported clearance of chlamydia (<a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>). Cure occurred in 20/21 women in the quinolone group (95.2%, 95% CI 77% to 99%) and 25/25 women in the cephalosporin group (100%, 95% CI 86% to 100%). </p> <p>This suggests that if the rate of microbiological clearance of <i>C trachomatis</i> in women using regimens including cephalosporin was 100%, the rate using regimens including quinolones would be 77% to 99%. </p> </section> <section id="CD010285-sec-0085"> <h6 class="title">2.4. Microbiological clearance of gonorrhoea</h6> <p>Three studies reported clearance of gonorrhoea (<a href="./references#CD010285-bbs2-0038" title="Wendel GD Jr, CoxSM , BawdonRE , TheriotSK , HeardMC , NoblesBJ . A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. American Journal of Obstetrics and Gynecology1991;164(5 Pt 2):1390-6. ">Wendel 1991</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0002" title="ArredondoJL , DiazV , GaitanH , MaradiegueE , OyarzúnE , PazR , et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clinical Infectious Diseases1997;24(2):170-8. ">Arredondo 1997</a>). Cure occurred in 27/30 women in the quinolone group (90%, 95% CI 74% to 96%) and 20/21 women in the cephalosporin group (95.2%, 95% CI 77% to 99%). </p> <p>This suggests that if the rate of microbiological clearance of <i>N gonorrhoeae </i>in women using regimens including cephalosporin was 95%, the rate using regimens including quinolone would be 74% to 96%. </p> </section> <section id="CD010285-sec-0086"> <h6 class="title">2.5. Laparoscopic evidence of resolution of pelvic inflammatory disease based on physician opinion </h6> <p>We found no data for laparoscopic evidence of resolution of PID.</p> </section> <section id="CD010285-sec-0087"> <h6 class="title">2.6. Length of stay (for inpatient care)</h6> <p>We found no data suitable for analysis for the length of hospital stay. Fischbach and colleagues admitted women for IV treatment for two to five days, followed by seven to 12 days of PO therapy, without further details (<a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>). </p> </section> <section id="CD010285-sec-0088"> <h6 class="title">2.7. Fertility outcome</h6> <p>No studies reported live birth rate.</p> </section> </section> </section> <section id="CD010285-sec-0089"> <h4 class="title">3. Regimens containing nitroimidazoles versus regimens without the use of nitroimidazoles</h4> <p>Seventeen studies compared multiple or single antibiotics associated with or without nitroimidazoles in mild‐moderate PID (<a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>) or severe PID (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>). </p> <section id="CD010285-sec-0090"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD010285-sec-0091"> <h5 class="title">3.1. Effectiveness</h5> <section id="CD010285-sec-0092"> <h6 class="title">3.1a. Clinical cure in mild‐moderate pelvic inflammatory disease</h6> <p>We included six studies in the analysis of clinical cure in mild‐moderate PID (<a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). All studies used metronidazole as the nitroimidazole. There was probably little or no difference in rates of cure between metronidazole or no metronidazole in mild‐moderate PID (RR 1.02, 95% CI 0.95 to 1.09; 6 studies, 2660 women; I<sup>2</sup> = 50%; moderate‐quality evidence) (<a href="./references#CD010285-fig-0024" title="">Analysis 3.1</a>; <a href="#CD010285-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD010285-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> </div> <p>This suggests that if the rate of cure in women with mild‐moderate PID using regimens including nitroimidazoles was 77%, the rate using no nitroimidazoles would be 72% to 83%. </p> <p>Sensitivity analysis restricted to the three studies at low risk of bias shows little or no difference in rates of cure between the use or not of metronidazole in mild‐moderate PID (RR 1.05, 95% CI 1.00 to 1.12; 3 studies, 1434 women; I<sup>2</sup> = 0%; high‐quality evidence) (<a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). (<a href="./references#CD010285-fig-0025" title="">Analysis 3.2</a>). </p> <p>In this sensitive analysis, this suggests that if the rate of cure in women with mild‐moderate PID using regimens including nitroimidazoles was 75%, the rate using no nitroimidazoles would be 74% to 87%. </p> </section> <section id="CD010285-sec-0093"> <h6 class="title">3.1b. Clinical cure in severe pelvic inflammatory disease</h6> <p>Eleven studies evaluated nitroimidazole in severe PID and all studies used metronidazole (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>). There was probably little or no difference in rates of cure between the use or not of metronidazole in severe PID (RR 0.96, 95% CI 0.92 to 1.01; 11 studies, 1383 women; I<sup>2</sup> = 3%; moderate‐quality evidence) (<a href="./references#CD010285-fig-0026" title="">Analysis 3.3</a>; <a href="#CD010285-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD010285-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.3 Effectiveness of cure in severe PID." data-id="CD010285-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.3 Effectiveness of cure in severe PID. </p> </div> </div> </div> <p>This suggests that if the rate of cure in women with severe PID using regimens including nitroimidazoles was 83%, the rate using no nitroimidazoles would be 77% to 83%. </p> </section> </section> <section id="CD010285-sec-0094"> <h5 class="title">3.2. Adverse events</h5> <section id="CD010285-sec-0095"> <h6 class="title">3.2.1. Antibiotic‐related adverse effects leading to discontinuation of therapy</h6> <p>We analyzed 17 studies of antibiotic‐related adverse effects leading to discontinuation of therapy (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>; <a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). We are uncertain of the effect of discontinuation of therapy between groups due to adverse effects (RR 1.05, 95% CI 0.69 to 1.61; 17 studies, 4021 women; I<sup>2</sup> = 0%; low‐quality evidence). Of note, 10/17 RCTs did not contribute data to the analysis because the authors reported no adverse effects (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>; <a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>; <a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>; <a href="./references#CD010285-bbs2-0015" title="GiraudJR , ChartierM , Ciraru VigneronN , BecueJ , LandesP , LengJJ , et al. A comparison of the efficacy of and tolerance to Augmentin used alone and as one of three drugs used to treat acute upper genital tract infections. Results of a multicentre trial 152 cases [Comparaison de l'efficacite et de la tolerance de l'Augmentine en monotherapie versus triple association dans le traitment des infections genitales hautes aigues. Resultats d'une etude multicentrique portant sur 152 cas]. Contraception, Fertilite, Sexualite1989;17(10):941-8. ">Giraud 1989</a>; <a href="./references#CD010285-bbs2-0016" title="HeinonenPK , TeisalaK , MiettinenA , AineR , PunnonenR , GrönroosP . A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scandinavian Journal of Infectious Diseases. Supplementum1989;60:66-73. ">Heinonen 1989</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>; <a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>). Only six studies reported adverse effects leading to discontinuation of treatment, yielding a rate of 2% of severe adverse effects (95% CI 1.5% to 2.7%) in the nitroimidazole group and 1.9% (95% CI 1.4% to 2.6%) in the no nitroimidazole group.  </p> <p>This suggests that if the rate of adverse outcomes in women with PID using regimens including nitroimidazoles was 2%, the rate using no nitroimidazoles would be 1% to 3%. </p> <p>Data are depicted in <a href="./full#CD010285-tbl-0003">summary of findings Table 3</a>. </p> </section> </section> <section id="CD010285-sec-0096"> <h5 class="title">Secondary outcomes</h5> <section id="CD010285-sec-0097"> <h6 class="title">3.3. Microbiological clearance of chlamydia</h6> <p>This is not applicable since nitroimidazoles do not have activity against chlamydia.</p> </section> <section id="CD010285-sec-0098"> <h6 class="title">3.4. Microbiological clearance of gonorrhoea</h6> <p>This is not applicable since nitroimidazoles do not have activity against gonorrhoea.</p> </section> <section id="CD010285-sec-0099"> <h6 class="title">3.5. Laparoscopic evidence of resolution of pelvic inflammatory disease based on physician opinion </h6> <p>We found no data for laparoscopic evidence of resolution of PID.</p> </section> <section id="CD010285-sec-0100"> <h6 class="title">3.6. Length of stay (for inpatient care)</h6> <p>Burchell and colleagues did not give details of the length of hospital stay: the authors mentioned that "ampicillin plus metronidazole in group II began with four 1 g intravenous doses given at 6‐hourly intervals and then 400 mg 8‐hourly orally for 14 days" and in Table III stated, "patient response after 4 days treatment" (<a href="./references#CD010285-bbs2-0007" title="BurchellHJ , CronjeHS , De WetJI . Efficacy of different antibiotics in the treatment of pelvic inflammatory disease. South African Medical Journal1987;72:248-9. ">Burchell 1987</a>). </p> <p>Ciraru‐Vigneron and colleagues reported that women treated with amoxicillin plus clavulanate had a stay of 3.6 days and with ampicillin plus gentamicin plus metronidazole had a stay of 3.7 days (<a href="./references#CD010285-bbs2-0008" title="Ciraru-VigneronN , BercauG , SauvanetE , Nguyen Tan LungR , FeltenA , LeauteJB , et al. The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections [L'association amoxicilline-acide clavulanique comparée à la triple association ampicilline-gentamicine-métronidazole dans le traitement des infections utéro-annexielles sévères]. Pathologie Biologie1986;34(5 Pt 2):665-8. ">Ciraru‐Vigneron 1986</a>). </p> <p>Buisson and colleagues reported that the mean treatment for the amoxicillin plus clavulanate group was four days followed by a mean of 17 days of PO therapy, and for ampicillin plus gentamicin plus metronidazole, it was seven days per protocol, due to the use of gentamicin, followed by ampicillin plus metronidazole until clinical improvement (<a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>). </p> <p>Ciraru‐Vigneron and colleagues reported that the mean duration of IV therapy was 7.6 (SD 2.1) days in the amoxicillin plus clavulanate group and 7.7 (SD 2.2) days in the ampicillin plus gentamicin plus metronidazole group. They did not specify if the PO treatment following IV treatment was performed in hospital, but they were similar (11.2 (SD 4.8) days with amoxicillin plus clavulanate and 11.1 (SD 6.6) days with ampicillin plus gentamicin plus metronidazole) (<a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>). </p> <p>Crombleholme and colleagues reported that treatment was for 14 days, starting with IV infusion and switched to PO, but they did not report if PO therapy was in hospital (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>). In their previous study, IV treatment length was mentioned as at least five days, without further details (<a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>). </p> <p>Fischbach and colleagues admitted women for IV treatment for two to five days, followed by seven to 12 days of PO therapy, without further details (<a href="./references#CD010285-bbs2-0014" title="FischbachF , DeckardtR , GraeffH . Ciprofloxacin/metronidazol vs. cefoxitin/doxycyclin: vergleich zweier therapieschemata zur behandlung der akuten pelvinen infektion. Geburtshilfe und Frauenheilkunde1994;54:337-40. ">Fischbach 1994</a>). </p> </section> <section id="CD010285-sec-0101"> <h6 class="title">3.7. Fertility outcome</h6> <p>No studies reported live birth rate.</p> </section> <section id="CD010285-sec-0102"> <h6 class="title">3.8. Other analyses</h6> <p>We explored publication bias through visual assessment of funnel plot asymmetry when there were data from 10 or more trials in the same analysis. We constructed a funnel plot for severe PID using regimens containing nitroimidazoles versus no nitroimidazoles (<a href="./references#CD010285-fig-0026" title="">Analysis 3.3</a>, <a href="#CD010285-fig-0012">Figure 12</a>) and noted some asymmetry in the plot, suggestive of potential publication bias. Although it is usually impossible to know the precise mechanism for funnel plot asymmetry, publication bias could explain the presence of an asymmetrical funnel plot. </p> <div class="figure" id="CD010285-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3.3 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles." data-id="CD010285-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3.3 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles. </p> </div> </div> </div> </section> </section> </section> <section id="CD010285-sec-0103"> <h4 class="title">4. Regimens containing clindamycin plus aminoglycoside versus regimens containing quinolone </h4> <p>Three studies compared clindamycin plus aminoglycoside versus quinolone in mild‐moderate PID (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>) or severe PID (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>). </p> <section id="CD010285-sec-0104"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD010285-sec-0105"> <h5 class="title">4.1. Effectiveness</h5> <section id="CD010285-sec-0106"> <h6 class="title">4.1a. Clinical cure in mild‐moderate pelvic inflammatory disease</h6> <p>One study compared clindamycin with an aminoglycoside (gentamicin) versus a quinolone (ciprofloxacin) (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>). We are uncertain whether clindamycin plus aminoglycoside improves rates of cure in mild‐moderate PID compared to quinolone (RR 0.88, 95% CI 0.69 to 1.13; 1 study, 25 women; I<sup>2</sup> = 0%; very low‐quality evidence) (<a href="./references#CD010285-fig-0028" title="">Analysis 4.1</a>;<a href="#CD010285-fig-0013">Figure 13</a>). </p> <div class="figure" id="CD010285-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease." data-id="CD010285-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-13.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease. </p> </div> </div> </div> <p>This suggests that if the rate of clinical cure in women with mild‐moderate PID using regimens including quinolone was 2%, the rate using regimens including clindamycin and aminoglycoside would be 62% to 96%. </p> </section> <section id="CD010285-sec-0107"> <h6 class="title">4.1b. Clinical cure in severe pelvic inflammatory disease</h6> <p>We included two studies in the analysis of clinical cure in severe PID (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>). We are uncertain whether clindamycin plus aminoglycoside improves rates of cure for severe PID compared to quinolones (RR 1.02, 95% CI 0.87 to 1.19; 2 studies, 151 women; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD010285-fig-0029" title="">Analysis 4.2</a>;<a href="#CD010285-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD010285-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.2 Effectiveness of cure in severe pelvic inflammatory disease." data-id="CD010285-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-14.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.2 Effectiveness of cure in severe pelvic inflammatory disease. </p> </div> </div> </div> <p>The evidence suggests that if the rate of clinical cure in women with severe PID using regimens including quinolone was 80%, the rate using regimens including clindamycin and aminoglycoside would be 71% to 89%. </p> </section> </section> <section id="CD010285-sec-0108"> <h5 class="title">4.2. Adverse events</h5> <section id="CD010285-sec-0109"> <h6 class="title">4.2.1. Antibiotic‐related adverse effects leading to discontinuation of therapy</h6> <p>The incidence of antibiotic‐related adverse effects leading to discontinuation of therapy with clindamycin with aminoglycoside was 0% (95% CI 0% to 4.4%) and with quinolone was 5% (95% CI 1.9% to 12%). We are uncertain whether clindamycin plus aminoglycoside improves the rates of discontinuation compared to quinolones (RR 0.21, 95% CI 0.02 to 1.72; 3 studies, 163 women; I<sup>2</sup> = 0%; very low‐quality evidence) (<a href="./references#CD010285-fig-0030" title="">Analysis 4.3</a>). </p> <p>This suggests that if the rate of adverse outcomes in women with PID using regimens including quinolone was 5%, the rate using regimens with clindamycin and aminoglycoside would be 0% to 4.4%. </p> <p>Data are depicted in <a href="./full#CD010285-tbl-0004">summary of findings Table 4</a>. </p> </section> </section> <section id="CD010285-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD010285-sec-0111"> <h6 class="title">4.3. Microbiological clearance of chlamydia</h6> <p>Three studies reported chlamydia clearance (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>; <a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>). Cure occurred in 10/10 women in the clindamycin plus aminoglycoside group (100%, 95% CI 72% to 100%) and in 11/12 women in the quinolone group (92%, 95% CI 65% to 99%). </p> <p>This suggests that if the rate of microbiological clearance of <i>C trachomatis</i> in women using regimens including quinolone was 80%, the rate using regimens including clindamycin and aminoglycoside would be 72% to 100%. </p> </section> <section id="CD010285-sec-0112"> <h6 class="title">4.4. Microbiological clearance of gonorrhoea</h6> <p>Three studies reported gonorrhoea clearance (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>; <a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>; <a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>). Cure occurred in 44/44 women in the clindamycin plus aminoglycoside group (100%, 95% CI 92% to 100%) and in 41/41 women in the quinolone group (100%, 95% CI 91% to 100%). </p> <p>This suggests that if the rate of microbiological clearance of <i>N gonorrhoeae </i>in women using regimens including quinolone was 100%, the rate using regimens including clindamycin and aminoglycoside would be 92% to 100%. </p> </section> <section id="CD010285-sec-0113"> <h6 class="title">4.5. Laparoscopic evidence of resolution of pelvic inflammatory disease based on physician opinion </h6> <p>We found no data for laparoscopic evidence of resolution of PID.</p> </section> <section id="CD010285-sec-0114"> <h6 class="title">4.6. Length of stay (for inpatient care)</h6> <p>We found no data suitable for analysis for length of hospital stay. Crombleholme and colleagues reported that treatment was for 14 days, starting with IV infusion and then switched to PO, but they did not report if PO therapy was in hospital (<a href="./references#CD010285-bbs2-0012" title="CrombleholmeWR , SchachterJ , Ohm-SmithM , LuftJ , WhiddenR , SweetRL . Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. American Journal of Medicine1989;87(Suppl 5A):142S-7S. ">Crombleholme 1989</a>). Apuzzio and colleagues did not give many details of the length of stay. They mentioned that women received IV antibiotics for three to five days until they were asymptomatic for 24 hours (<a href="./references#CD010285-bbs2-0001" title="ApuzzioJJ , StankiewiczR , GaneshV , JainS , KaminskiZ , LouriaD . Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. American Journal of Medicine1989;87(5A):148S-51S. ">Apuzzio 1989</a>). Likewise, Thadepalli reported that women received IV ciprofloxacin for three or more days, followed by PO ciprofloxacin for about one week (<a href="./references#CD010285-bbs2-0035" title="ThadepalliH , MathaiD , ScottieR , BansalMB , SavageE . Ciprofloxacin monotherapy for acute pelvic infections: a comparison with clindamycin plus gentamicin. Obstetrics and Gynaecology1991;78(4):696-701. ">Thadepalli 1991</a>). </p> </section> <section id="CD010285-sec-0115"> <h6 class="title">4.7. Fertility outcome</h6> <p>No studies reported live birth rate.</p> </section> </section> </section> <section id="CD010285-sec-0116"> <h4 class="title">5. Regimens containing clindamycin plus aminoglycoside versus regimens containing cephalosporin </h4> <p>Ten studies compared clindamycin plus aminoglycoside versus cephalosporin in mild‐moderate PID (<a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>) or severe PID (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). Studies from <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a> and <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a> had both populations with mild‐moderate and severe PID, thus they were used in both analyses. </p> <section id="CD010285-sec-0117"> <h5 class="title">Primary outcomes</h5> </section> <section id="CD010285-sec-0118"> <h5 class="title">5.1. Effectiveness</h5> <section id="CD010285-sec-0119"> <h6 class="title">5.1a. Clinical cure in mild‐moderate pelvic inflammatory disease</h6> <p>We analyzed two studies for clinical cure in mild‐moderate PID (<a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>). There was probably little or no difference between clindamycin plus aminoglycoside and cephalosporin in rates of cure for mild‐moderate PID (RR 1.02, 95% CI 0.95 to 1.09; 2 studies, 150 women; I<sup>2</sup> = 0%; low‐quality evidence) (<a href="./references#CD010285-fig-0031" title="">Analysis 5.1</a>; <a href="#CD010285-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD010285-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Regimens containing clindamycin plus aminoglycoside versus cephalosporin, outcome: 5.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease." data-id="CD010285-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-15.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Regimens containing clindamycin plus aminoglycoside versus cephalosporin, outcome: 5.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease. </p> </div> </div> </div> <p>This suggests that if the rate of clinical cure in women with mild‐moderate PID using regimens including cephalosporin was 96%, the rate using regimens including clindamycin and aminoglycoside would be 91% to 99%. </p> </section> <section id="CD010285-sec-0120"> <h6 class="title">5.1b. Clinical cure in severe pelvic inflammatory disease</h6> <p>We included 10 studies in the analysis of clinical cure in severe PID (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). There was probably little or no difference between clindamycin plus aminoglycoside and cephalosporin in rates of cure of severe PID (RR 1.00, 95% CI 0.95 to 1.06; 10 studies, 959 women; I<sup>2</sup> = 21%; moderate‐quality evidence) (​​<a href="./references#CD010285-fig-0032" title="">Analysis 5.2</a>;​​​​ <a href="#CD010285-fig-0016">Figure 16</a>). </p> <div class="figure" id="CD010285-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="5.2 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing clindamycin plus aminoglycoside versus cephalosporin." data-id="CD010285-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-16.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>5.2 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing clindamycin plus aminoglycoside versus cephalosporin. </p> </div> </div> </div> <p>This suggests that if the rate of clinical cure in women with severe PID using regimens including cephalosporin was 84%, the rate using regimens including clindamycin and aminoglycoside would be 80% to 87%. </p> </section> </section> <section id="CD010285-sec-0121"> <h5 class="title">5.2. Adverse events</h5> <section id="CD010285-sec-0122"> <h6 class="title">5.2.1. Antibiotic‐related adverse effects leading to discontinuation of therapy</h6> <p>We included 10 studies in the analysis of antibiotic‐related adverse effects leading to discontinuation of therapy (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). We are uncertain whether clindamycin plus aminoglycoside improves the rates of discontinuation of treatment compared to cephalosporin (RR 0.78, 95% CI 0.18 to 3.42; 10 studies, 1172 women; I<sup>2</sup> = 0%; very low‐quality evidence) (<a href="./references#CD010285-fig-0033" title="">Analysis 5.3</a>). </p> <p>This suggests that if the rate of adverse outcomes in women with PID using regimens including cephalosporin was 4%, the rate using regimens with clindamycin and aminoglycoside would be 0% to 2%. </p> <p>Data are depicted in <a href="./full#CD010285-tbl-0005">summary of findings Table 5</a>. </p> </section> </section> <section id="CD010285-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD010285-sec-0124"> <h6 class="title">5.3. Microbiological clearance of chlamydia</h6> <p>Five studies reported chlamydia clearance (<a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). Cure occurred in 53/56 women in the cephalosporin group (94.6%, 95% CI 85% to 98%) and in 75/78 women in the clindamycin plus aminoglycoside group (96%, 95% CI 89% to 99%). </p> <p>This suggests that if the rate of microbiological clearance of <i>C trachomatis</i> in women using regimens including cephalosporin was 95%, the rate using regimens including clindamycin and aminoglycoside would be 89% to 99%. </p> </section> <section id="CD010285-sec-0125"> <h6 class="title">5.4. Microbiological clearance of gonorrhoea</h6> <p>Five studies reported gonorrhoea clearance (<a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). Cure occurred in 96/96 women in the clindamycin plus aminoglycoside group (100%, 95% CI 96% to 100%) and 115/117 women in the cephalosporin group (98%, 95% CI 94% to 99%). </p> <p>This suggests that if the rate of microbiological clearance of <i>N gonorrhoeae </i>in women using regimens including cephalosporin was 98%, the rate using regimens including clindamycin and aminoglycoside would be 96% to 100%. </p> </section> <section id="CD010285-sec-0126"> <h6 class="title">5.5. Laparoscopic evidence of resolution of pelvic inflammatory disease based on physician opinion </h6> <p>We found no data for laparoscopic evidence of resolution of PID.</p> </section> <section id="CD010285-sec-0127"> <h6 class="title">5.6. Length of stay (for inpatient care)</h6> <p>Seven studies provided insufficient data for analysis of length of hospital stay (<a href="./references#CD010285-bbs2-0029" title="RoyS , WilkinsJ . Cefotaxime in the treatment of female pelvic soft tissue infections. Infection1985;13(Suppl 1):S56-61. ">Roy 1985</a>; <a href="./references#CD010285-bbs2-0034" title="SweetRL , Ohm-SmithM , LandersDV , RobbieMO . Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology1985;152:808-17. ">Sweet 1985</a>; <a href="./references#CD010285-bbs2-0030" title="RoyS , WilkinsJ , MarchCM , SoleraNC , GalvanNI , ResslerRL , et al. A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass. Clinical Therapeutics1990;12(Suppl C):53-73. ">Roy 1990</a>; <a href="./references#CD010285-bbs2-0037" title="WaltersMD , GibbsRS . A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstetrics and Gynecology1990;75(5):867-72. ">Walters 1990</a>; <a href="./references#CD010285-bbs2-0021" title="LandersDV , Wolner-HanssenP , PaavonenJ , ThorpeE , KiviatN , Ohm-SmithM , et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. American Journal of Obstetrics and Gynecology1991;164(3):849-58. ">Landers 1991</a>; <a href="./references#CD010285-bbs2-0024" title="MariaB , DublanchetA , StreckerJ , DennemarkN , GenazzaniA , FiorettiP , et al. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. Acta Obstetricia et Gynecologica Scandinavica1992;71(2):129-34. ">Maria 1992</a>; <a href="./references#CD010285-bbs2-0004" title="BalbiG , PiscitelliV , Di GraziaF , MartiniS , BalbiC , CardoneA . Acute pelvic inflammatory disease: comparison of therapeutic protocols [Malattia infiammatoria pelvica acuta: protocolli terapeutici a confronto]. Minerva Ginecologica1996;48(1-2):19-23. ">Balbi 1996</a>). Three studies provided the mean and SDs of hospital stay, or range of days (<a href="./references#CD010285-bbs2-0033" title="SoperDE , DespresB . A comparison of two antibiotic regiments for treatment of pelvic inflammatory disease. Obstetrics and Gynecology1988;72(7):7-12. ">Soper 1988</a>; <a href="./references#CD010285-bbs2-0025" title="MartensMG , FaroS , HammillH , MaccatoM , RiddleGD , LaPreadE . Comparison of cefotaxime, cefoxitin and clindamycin plus gentamicin in the treatment of uncomplicated and complicated pelvic inflammatory disease. Journal of Antimicrobial Chemotherapy1990;26(Suppl A):37-43. ">Martens 1990</a>; <a href="./references#CD010285-bbs2-0017" title="HemsellDL , LittleBB , FaroS , SweetRL , LedgerWJ , BerkeleyAS , et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases1994;19(4):720-7. ">Hemsell 1994</a>). The mean length of stay for the cephalosporin group varied from 5.8 days to 9.6 days (range 3 days to 18 days) and in the clindamycin plus aminoglycoside group varied from 5.8 days to 9.8 days (range 2 days to 25 days). </p> </section> <section id="CD010285-sec-0128"> <h6 class="title">5.7. Fertility outcome</h6> <p>No studies reported live birth rate.</p> </section> </section> </section> <section id="CD010285-sec-0129"> <h4 class="title">Other analyses</h4> <p>We were unable to conduct our planned subgroup analyses due to insufficient data in the included studies. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010285-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010285-sec-0130"></div> <section id="CD010285-sec-0131"> <h3 class="title" id="CD010285-sec-0131">Summary of main results</h3> <p>We included 39 trials with 6894 women in the review. We found no clear evidence of a difference between any of the regimens studied in terms of effectiveness or safety. </p> <p>The only comparison that clearly suggested a difference between the interventions was the sensitivity analysis of cases of mild‐moderate PID for the comparison macrolide (azithromycin) versus tetracycline (doxycycline). When we limited analysis to the single study at low risk of bias, moderate‐quality evidence suggested that azithromycin was superior to doxycycline in achieving clinical cure (<a href="./full#CD010285-tbl-0001">summary of findings Table 1</a>). </p> <p>Some guidelines have recommended the use of nitroimidazoles for treating PID (<a href="./references#CD010285-bbs2-0177" title="RossJ , JudlinP , NilasL . European guidelines of the management of pelvic inflammatory disease. International Journal of STD and AIDS2007;18:662-6.">Ross 2007</a>; <a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>). We found no conclusive evidence of a difference between the use or not of nitroimidazoles (metronidazole) in rates of cure in either mild‐moderate or severe PID. There was also no clear evidence of a difference in rates of adverse effects. </p> </section> <section id="CD010285-sec-0132"> <h3 class="title" id="CD010285-sec-0132">Overall completeness and applicability of evidence</h3> <p>Although we conducted comprehensive searches to identify all published and unpublished RCTs, this systematic review included trials at high risk of bias and consequently with low confidence in the estimate of effect (see <a href="./full#CD010285-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010285-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010285-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010285-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010285-tbl-0005">summary of findings Table 5</a>). When we used ITT analysis, there was substantial heterogeneity in the azithromycin trial results, which may limit our conclusions. </p> <p>Data were lacking for several of our secondary outcomes. None of the included studies reported data on fertility or laparoscopic evidence of PID resolution, and data were very scant on length of hospital stay. </p> <p>The applicability of the evidence to the target population (women of reproductive age diagnosed with PID) was broad because the included trials were conducted in different clinical settings and implemented varying diagnostic approaches. Additionally, the interventions analyzed in the review are available in various clinical settings and represent the most frequently used therapeutic schemes in current clinical practice. Given these factors, we consider that the evidence identified applies to a wide range of women with PID varying in disease severity, age, geographical location, and diagnostic criteria, which provides external validity. </p> <p>Our results on the use or no use of nitroimidazole should be interpreted with caution. The rationale for using nitroimidazole is to cover anaerobic bacteria and it is commonly used with other drugs (e.g. doxycycline and ceftriaxone). In most of the comparisons, anaerobic coverage was given with other medications, such as moxifloxacin (<a href="./references#CD010285-bbs2-0018" title="HeystekM , RossJD , PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD &amp; AIDS2009;20(10):690-5. ">Heystek 2009</a>; <a href="./references#CD010285-bbs2-0003" title="AşicioğluO , GungordukK , OzdemirA , ErtasIE , YildirimG , SanciM , et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2013;171(1):116-21. ">Aşicioğlu 2013</a>), amoxicillin plus clavulanate (<a href="./references#CD010285-bbs2-0036" title="TisonE , MarpeauL , PignéA , TessierF , BarratJ . Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: Augmentin [Traitement des salpingites aiguës non chlamydiennes. Etude de l'efficacité et de la tolérance d'un antibiotique en monothérapie: l'Augmentin]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1988;17(4):513-9. ">Tison 1988</a>; <a href="./references#CD010285-bbs2-0006" title="BuissonP , MulardC , BaudetJ , BernardP , MaresP , MonteroM , et al. Treatment of upper genital infections in women. Multicenter study of the comparative efficacy and tolerance of an amoxicillin-clavulanic acid combination and of a triple antibiotic combination [Étude multicentrique de l'efficacité et de la tolérance comparées de l'association amoxicilline-acide clavulanique et d'une triple association antibiotique]. Revue Francaise de Gynecologie et d'Obstetrique1989;84(10):699-703. ">Buisson 1989</a>; <a href="./references#CD010285-bbs2-0009" title="Ciraru-VigneronN , BarrierJ , BecueJ , ChartierM , GiraudJR , LandesP , et al. Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease. Pharmatherapeutica1989;5(5):312-9. ">Ciraru‐Vigneron 1989</a>), ampicillin plus sulbactam (<a href="./references#CD010285-bbs2-0010" title="CrombleholmeD , LandersD , Ohm-SmithM , RobbieMO , HadleyWK , DeKayV , et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs1986;31(Suppl 2):11-3. ">Crombleholme 1986</a>; <a href="./references#CD010285-bbs2-0011" title="CrombleholmeWR , Ohm-SmithM , RobbieMO , DeKayV , SweetRL . Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. American Journal of Obstetrics and Gynecology1987;156(2):507-12. ">Crombleholme 1987</a>), or clindamycin (<a href="./references#CD010285-bbs2-0022" title="LeboeufD , RoussetD , CacaultJA , EngelmanP . Prospective randomized trial comparing the efficacy and the tolerance of clindamycin-gentamicin versus metronidazole-gentamicin in acute utero-adnexal infections in hospitalized patients [Essai prospectif randomise comparant l'efficacite et la tolerance de la clindamycine-gentamycine versus metronidazole-gentamycine dans les infections utero-annexielles aigues chez des patientes hospitalisees]. Revue Francaise de Gynecologie et d'Obstetrique1987;82(1):9-15. ">Leboeuf 1987</a>; <a href="./references#CD010285-bbs2-0032" title="SirayapiwatP , ChaithongwongwatthanaS , TirawatnapongS . Triple therapies versus clindamycin plus gentamicin in the treatment of acute pelvic inflammatory disease: a randomized controlled trial. Thai Journal of Obstetrics and Gynaecology2002;14:215-21. ">Sirayapiwat 2002</a>), and this may explain the lack of evidence of the superiority on the use of nitroimidazole. Data derived from the tabular section of the ClinicalTrials.gov from the study that compared doxycycline plus metronidazole versus doxycycline plus placebo may clarify this topic (<a href="./references#CD010285-bbs2-0039" title="WiesenfeldH , HillierS , MeynL , RabeL , MacioI , PriestC , et al. Impact of metronidazole on clearance of anaerobes in women with acute pelvic inflammatory disease: the ACE trial. American Journal of Obstetrics and Gynecology2017;217(6):714. [DOI: doi.org/10.1016/J.AJOG.2017.08.081]">Wiesenfeld 2017</a>). These authors reported a clinical cure in 96/116 women in the metronidazole group, compared to 94/117 women in the placebo group. There was probably little or no difference between groups (RR 1.03, 95% CI 0.91 to 1.16; 233 women; some concerns regarding of bias) in clinical cure after three days of treatment. In contrast, metronidazole probably improves the rates of clearance of anaerobic bacteria compared to placebo (RR 1.42, 95% CI 1.03 to 1.95; 40 women; some concerns regarding of bias; NNTB 3) when endometrial culture was employed for diagnosis, using a per‐protocol analysis. In an ITT analysis (six women were lost to follow‐up in each group), there is probably little or no difference  in use or not metronidazole (RR 1.38, 95% CI 0.89 to 2.15; 52 women; some concerns regarding of bias). Without the final published data, these results must be interpreted with caution. </p> <p>PID can be life or fertility threatening, and treatment is routinely started before laboratory cultures or laparoscopic confirmation. In some cases, women were subsequently diagnosed with another condition; however, we included all women in our ITT analysis, in accordance with our review protocol. </p> </section> <section id="CD010285-sec-0133"> <h3 class="title" id="CD010285-sec-0133">Quality of the evidence</h3> <p>Most of the 39 included studies had unclear or high risk of bias in most domains, and only three were at low risk of bias in most domains (<a href="./references#CD010285-bbs2-0028" title="RossJD , CronjéHS , PaszkowskiT , RakocziI , VildaiteD , KureishiA , et al, MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually Transmitted Infections2006;82(6):446-51. ">Ross 2006</a>; <a href="./references#CD010285-bbs2-0031" title="SavarisRF , TeixeiraLM , TorreTG , EdelweissMIA , MoncadaJ , SchachterJ . Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstetrics and Gynecology2007;110(1):53-60. ">Savaris 2007</a>; <a href="./references#CD010285-bbs2-0020" title="JudlinP , LiaoQ , LiuZ , ReimnitzP , HampelB , ArvisP . Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG2010;117:1475-84. ">Judlin 2010b</a>). The remaining studies had several limitations, for instance, 26 trials did not clearly define randomization, and there was potential performance and detection bias in 20 studies (<a href="#CD010285-fig-0003">Figure 3</a>). </p> <p>The overall quality of the evidence ranged from very low to high, the main limitations being serious risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency, and serious imprecision. There was substantial heterogeneity in the comparison between azithromycin and doxycycline (I<sup>2</sup> = 72%; Figure 4), and in the comparison of nitroimidazole versus no nitroimidazole (I<sup>2</sup> = 60%; Figure 10). Imprecision was related to suboptimal sample sizes and the low number of studies for some comparisons. </p> <p>Of note, in <a href="./references#CD010285-fig-0017" title="">Analysis 1.1</a>, if the results were considered as failure, instead of cure, the results analyzed using RR would not be consistent; however, using odds ratio, results would be consistent. By using OR, the results were similar, revealing similar interpretation of the results in either method of analysis (OR 1.95, 95% CI 0.66 to 7.72; 243 women, 2 studies, I<sup>2</sup> = 68%; very low‐quality evidence; data not shown). </p> <p>The quality of evidence for the outcomes analyzed is provided in <a href="./full#CD010285-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010285-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010285-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010285-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010285-tbl-0005">summary of findings Table 5</a>. The only high‐quality evidence was for the sensitivity analysis regarding the use (or not) of nitroimidazole. There was moderate‐quality evidence in the sensitivity analysis regarding the use of azithromycin in mild‐moderate cases of PID, in comparisons between the use or not of nitroimidazole for curing mild‐moderate or severe PID, and in comparisons between clindamycin plus aminoglycoside versus cephalosporins for curing severe PID. </p> <p>For all other comparisons, the evidence was low or very‐low quality.</p> </section> <section id="CD010285-sec-0134"> <h3 class="title" id="CD010285-sec-0134">Potential biases in the review process</h3> <p>An important limitation of this systematic review was the potential for measurement bias introduced by using the investigators' definitions of cure. There was a wide variation in methods used and a widely accepted objective outcome was lacking. Despite the clinical outcomes being relevant and their assessment being sufficient to understand the effects of interventions in the short term, the short‐term follow‐up only of most of the studies prevented a more detailed identification of long‐term sequelae. In addition, the inaccuracy of clinical diagnosis for PID and the wide variety of assessment criteria used for a clinical cure may have reduced the power of the analysis to detect a significant effect. For instance, some authors have used a reduction of 70% of initial pain over a period of time to define clinical cure. This approach may seem adequate; consider, however, two cases, both on the same 10‐point visual analog scale for pain: one woman started with a pain score of 10 out of 10 and the other with a pain score of 5 out of 10. After treatment, both cases report a pain score of 2. The former would be considered as cured and the latter not. Therefore, there is a clear need for core outcome measures to be developed that take into account the different effect measures in use. </p> <p>Some studies identified PID and endometritis separately but these were pooled for our analysis. </p> </section> <section id="CD010285-sec-0135"> <h3 class="title" id="CD010285-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>One previous meta‐analysis, published in 1993, formed the basis for the CDC guidelines (<a href="./references#CD010285-bbs2-0187" title="WalkerCK , KahnJG , WashingtonAE , PetersonHB , SweetRL . Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. Journal of Infectious Diseases1993;168(4):969-78.">Walker 1993</a>). The authors reported pooled clinical cure rates ranging from 75% to 94%, which is similar to the 2017 Cochrane Review (<a href="./references#CD010285-bbs2-0191" title="SavarisRF , FuhrichDG , DuarteRV , FranikS , RossJ . Antibiotic therapy for pelvic inflammatory disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD010285. [DOI: 10.1002/14651858.CD010285.pub2]">Savaris 2017</a>). The addition of two new references in our updated review did not change our previous results. Therefore, our results support the updated 2015 CDC guidelines (<a href="./references#CD010285-bbs2-0189" title="WorkowskiKA , BolanGA . Sexually transmitted diseases treatment guidelines, 2015. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report2015;64(RR-03):1-137.">Workowski 2015</a>), and the British Association of Sexual Health and HIV (<a href="./references#CD010285-bbs2-0152" title="RossJ , ColeM , EvansC ,   LyonsD , DeanG , CousinsD . United Kingdom national guideline for the management of pelvic inflammatory disease (2019 interim update). www.bashhguidelines.org/media/1217/pid-update-2019.pdf (accessed prior to 27 May 2020).">BASHH Guidelines 2019</a>), but not the inclusion of nitroimidazoles in treatment regimens. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010285-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. PID: pelvic inflammatory disease; RCT: randomised controlled trial." data-id="CD010285-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. PID: pelvic inflammatory disease; RCT: randomised controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010285-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010285-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.3 Effectiveness of cure in severe PID." data-id="CD010285-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), outcome: 1.3 Effectiveness of cure in severe PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.2 Effectiveness of cure in severe PID." data-id="CD010285-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.2 Effectiveness of cure in severe PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.3 Any antibiotic‐related adverse effect leading to discontinuation." data-id="CD010285-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Regimens containing quinolones versus cephalosporins, outcome: 2.3 Any antibiotic‐related adverse effect leading to discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.1 Effectiveness of cure in mild‐moderate PID." data-id="CD010285-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.1 Effectiveness of cure in mild‐moderate PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.3 Effectiveness of cure in severe PID." data-id="CD010285-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Regimens containing nitroimidazoles versus no nitroimidazoles, outcome: 3.3 Effectiveness of cure in severe PID. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3.3 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles." data-id="CD010285-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3.3 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing nitroimidazoles versus without nitroimidazoles. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease." data-id="CD010285-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.2 Effectiveness of cure in severe pelvic inflammatory disease." data-id="CD010285-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Regimens containing clindamycin plus aminoglycoside versus quinolone, outcome: 4.2 Effectiveness of cure in severe pelvic inflammatory disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Regimens containing clindamycin plus aminoglycoside versus cephalosporin, outcome: 5.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease." data-id="CD010285-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Regimens containing clindamycin plus aminoglycoside versus cephalosporin, outcome: 5.1 Effectiveness of cure in mild‐moderate pelvic inflammatory disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-FIG-16" target="_blank"><b></b></a></p> </div><img alt="5.2 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing clindamycin plus aminoglycoside versus cephalosporin." data-id="CD010285-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>5.2 Effectiveness of cure in severe pelvic inflammatory disease in regimens containing clindamycin plus aminoglycoside versus cephalosporin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-FIG-16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 1: Effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 1: Effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 2: Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 2: Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 3: Effectiveness of cure in severe PID" data-id="CD010285-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 3: Effectiveness of cure in severe PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 4: Any antibiotic‐related adverse effect leading to discontinuation use of macrolide versus tetracycline" data-id="CD010285-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline), Outcome 4: Any antibiotic‐related adverse effect leading to discontinuation use of macrolide versus tetracycline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 1: Effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 1: Effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 2: Effectiveness of cure in severe PID" data-id="CD010285-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 2: Effectiveness of cure in severe PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation" data-id="CD010285-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Regimens containing quinolones versus cephalosporins, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 1: Effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 1: Effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 2: Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 2: Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 3: Effectiveness of cure in severe PID" data-id="CD010285-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 3: Effectiveness of cure in severe PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 4: Any antibiotic‐related adverse effect leading to discontinuation" data-id="CD010285-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Regimens containing nitroimidazoles versus no nitroimidazoles, Outcome 4: Any antibiotic‐related adverse effect leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 1: Effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 1: Effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 2: Effectiveness of cure in severe PID" data-id="CD010285-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 2: Effectiveness of cure in severe PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation" data-id="CD010285-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Regimens containing clindamycin plus aminoglycoside versus quinolone, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 1: Effectiveness of cure in mild‐moderate PID" data-id="CD010285-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 1: Effectiveness of cure in mild‐moderate PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 2: Effectiveness of cure in severe PID" data-id="CD010285-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 2: Effectiveness of cure in severe PID </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010285-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/urn:x-wiley:14651858:media:CD010285:CD010285-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation" data-id="CD010285-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_t/tCD010285-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Regimens containing clindamycin plus aminoglycoside versus cephalosporin, Outcome 3: Any antibiotic‐related adverse effect leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/media/CDSR/CD010285/image_n/nCD010285-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010285-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Regimens containing macrolides (azithromycin) compared to regimens containing tetracycline (doxycycline) for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Azithromycin compared to doxycycline for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing azithromycin </p> <p><b>Comparison:</b> regimens containing doxycycline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with doxycycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>689 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>818 per 1000</p> <p>(740 to 876)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> </p> <p>(0.89 to 1.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 13</p> <p>NNTH 3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clinical cure</b> according to criteria established by study author </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> <p>Sensitivity analysis restricted to study at low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>627 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>848 per 1000</p> <p>(743 to 921)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> </p> <p>(1.10 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 5 (3 to 14)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 13–18 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>969 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>971 per 1000<br/>(940 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.96 to 1.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 16</p> <p>NNTH 29</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: range 13–18 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(30 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> </p> <p>(0.38 to 1.34)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 13</p> <p>NNTH 101</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>980 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(900 to 1000)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.98 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 10</p> <p>NNTH 8</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(741 to 1000)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.76 to 1.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(1 RCT)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Just 1 RCT found cases of <i>N gonorrhoeae</i><br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious inconsistency (I<sup>2</sup> = 72%).<br/><sup>c</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups.<br/><sup>d</sup>Downgraded one level for serious imprecision: single study with only 98 events.<br/><sup>e</sup>Downgraded two levels for very serious risk of bias: single unblinded study with poor reporting of methods. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Regimens containing macrolides (azithromycin) compared to regimens containing tetracycline (doxycycline) for pelvic inflammatory disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010285-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regimens containing quinolone compared to regimens containing cephalosporins for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Quinolone compared to cephalosporins for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> quinolone </p> <p><b>Comparison:</b> cephalosporins </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cephalosporins</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with quinolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>719 per 1000<br/>(677 to 760) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.98 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>772<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 9</p> <p>NNTH 64</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/>(622 to 766) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.91 to 1.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 7</p> <p>NNTH 15</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(5 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.24</b> </p> <p>(0.52 to 9.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1085<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6 RCTs (502 women) did not contribute to this analysis because the authors reported 0 events. </p> <p>NNTB 40</p> <p>NNTH 129</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>952 per 1000<br/>(773 to 992) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.84 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 4</p> <p>NNTH 11</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>952 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000<br/>(744 to 965) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13 </b><br/>(0.89 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 23</p> <p>NNTH 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups.<br/><sup>c</sup>Downgraded two levels for very serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only seven events overall. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regimens containing quinolone compared to regimens containing cephalosporins for pelvic inflammatory disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010285-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Regimens containing nitroimidazole compared to no nitroimidazole for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Nitroimidazole compared to regimens without use of nitroimidazole for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing nitroimidazole </p> <p><b>Comparison:</b> regimens containing no nitroimidazole </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no nitroimidazole</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with nitroimidazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>766 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781 per 1000<br/>(727 to 834) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.95 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2660<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 19</p> <p>NNTH 91</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: range 14–28 days</p> <p>Sensitivity analysis restricted to studies at low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> <p>(740 to 868)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(1.00 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 19</p> <p>NNTH 91</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by study authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: range 14–28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>832 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>804 per 1000<br/>(772 to 831) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> </p> <p>(0.92 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 15</p> <p>NNTH 76</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(13 to 32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.69 to 1.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4021<br/>(17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/17 studies (1088 women) did not contribute data to the analysis because the authors reported no events. </p> <p>NNTB 108</p> <p>NNTH 121</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not applicable, nitroimidazoles have no activity against chlamydia.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not applicable, nitroimidazoles have no activity against gonorrhoea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results were insufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies reported any fertility outcomes.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of selection, performance, detection, attrition, and reporting bias in one or more studies).<br/><sup>b</sup>Substantial inconsistency (I<sup>2</sup> = 50%). Not downgraded because of all inconsistency related to a single small study (30 women) which barely influenced the overall estimate.<br/><sup>c</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only 79 events overall. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Regimens containing nitroimidazole compared to no nitroimidazole for pelvic inflammatory disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010285-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing quinolone for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Clindamycin + aminoglycoside compared to quinolone for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing clindamycin + aminoglycoside </p> <p><b>Comparison:</b> regimens containing quinolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with quinolone</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clindamycin + aminoglycoside</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>867 per 1000</p> <p>(621 to 962)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> </p> <p>(0.69 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 3</p> <p>NNTH 6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/>(714 to 887) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.87 to 1.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 7</p> <p>NNTH 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> <p>(0 to 44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> </p> <p>(0.02 to 1.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 RCTs (25 women) did not contribute data to the analysis because the authors reported 0 events. </p> <p>NNTB 8</p> <p>NNTH 273</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(722 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.85 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (3 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 3</p> <p>NNTH 5</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(920 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR  1.00</b> (0.96 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (3 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias: single unblinded study with poor reporting of methods.<br/><sup>b</sup>Downgraded two levels for serious imprecision (though further downgrading not possible): confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, very few events overall.<br/><sup>c</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in both studies).<br/><sup>d</sup>Downgraded one level for serious imprecision: confidence intervals compatible with benefit in one or both groups, or with no difference between the groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing quinolone for pelvic inflammatory disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010285-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing cephalosporin for pelvic inflammatory disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Clindamycin + aminoglycoside compared to cephalosporin for PID</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Population:</b> women with PID </p> <p><b>Setting:</b> hospital ward or outpatient clinic </p> <p><b>Intervention:</b> regimens containing clindamycin + aminoglycoside </p> <p><b>Comparison:</b> regimens containing cephalosporin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of women<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cephalosporin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clindamycin + aminoglycoside</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Mild‐moderate PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>958 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>974 per 1000</p> <p>(911 to 993)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.95 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11</p> <p>NNTH 19</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Clinical cure</b> according to criteria established by authors </p> <p><b>Severe PID</b> </p> <p>Follow‐up: median 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>840 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>838 per 1000<br/>(801 to 870) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.95 to 1.06)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>959<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 21</p> <p>NNTH 22</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events:</b> any antibiotic‐related adverse event leading to discontinuation of therapy </p> <p>Follow‐up: mean 14 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(2 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.18 to 3.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1172<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/10 RCTs (617 women) did not contribute data to the analysis reported because the authors reported no events. </p> <p>NNTB 75</p> <p>NNTH 126</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Microbiological clearance</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> 946 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962 per 1000<br/>(893 to 987)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.94 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(5 RCTs)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 9</p> <p>NNTH 16</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>N gonorrhoeae</i> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>983 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000<br/>(962 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> (0.99 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 17</p> <p>NNTH 43</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Laparoscopic evidence of resolution of PID based on physician opinion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Length of stay (for inpatient care)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Reported results are not sufficient for analysis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fertility outcome</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the mean risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95 CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PID:</b> pelvic inflammatory disease; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (poor reporting of methods and high or unclear risk of performance and detection bias in one or more studies).<br/><sup>b</sup>Downgraded one level for serious imprecision, small overall sample size.<br/><sup>c</sup>Downgraded two levels for serious imprecision (though further downgrading not possible): confidence intervals compatible with benefit in one or both groups, or with no difference between the groups, only six events overall. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside compared to regimens containing cephalosporin for pelvic inflammatory disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/full#CD010285-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010285-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.89, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.10, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Effectiveness of cure in severe PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Any antibiotic‐related adverse effect leading to discontinuation use of macrolide versus tetracycline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.38, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Regimens containing macrolides (azithromycin) versus tetracycline (doxycycline)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010285-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Regimens containing quinolones versus cephalosporins</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Effectiveness of cure in severe PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Any antibiotic‐related adverse effect leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.52, 9.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Regimens containing quinolones versus cephalosporins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010285-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Regimens containing nitroimidazoles versus no nitroimidazoles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Sensitivity analysis by risk of bias: effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.00, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Effectiveness of cure in severe PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Any antibiotic‐related adverse effect leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Regimens containing nitroimidazoles versus no nitroimidazoles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010285-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside versus quinolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Effectiveness of cure in severe PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Any antibiotic‐related adverse effect leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside versus quinolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010285-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside versus cephalosporin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Effectiveness of cure in mild‐moderate PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Effectiveness of cure in severe PID <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Any antibiotic‐related adverse effect leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.18, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Regimens containing clindamycin plus aminoglycoside versus cephalosporin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010285.pub3/references#CD010285-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010285.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010285-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010285-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010285-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010285-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD010285-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010285-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010285-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD010285-note-0009">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010285\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010285\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010285\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010285\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010285\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010285.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010285.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010285.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010285.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010285.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720377499"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010285.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720377503"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010285.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dffac0a759377',t:'MTc0MDcyMDM3Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 